Tumor therapeutics and applications thereof
Anti-claudin 18.2 antibodies with high specificity and affinity are developed to diagnose and treat gastric and pancreatic cancers by targeting claudin 18.2, addressing the limitations of existing technologies in tumor therapy.
Patent Information
- Application Number
- JP2024146208
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-04-19
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-04-15
AI Technical Summary
Current technologies lack effective antibodies with high specificity and affinity for claudin 18.2, which is widely expressed in various malignant tumors, limiting their use in diagnosis and therapy.
Development of anti-claudin 18.2 antibodies, including humanized monoclonal antibodies with high specificity and affinity, capable of binding to claudin 18.2 and mediating cell killing effects.
The antibodies effectively diagnose and treat gastric and pancreatic cancers by specifically targeting claudin 18.2, demonstrating high binding affinity and cell-killing capabilities.
Smart Images

Figure 2024167313000001_ABST
Abstract
Description
[Technical Field]
[0001] The present disclosure relates to antibodies that recognize claudins, as well as methods for producing and applications of the same. [Background technology]
[0002] Claudin 18 is a member of the claudin family with highly tissue-specific distribution, and in normal tissues, it is found primarily in epithelial and endothelial cells of the stomach or lung. It is involved in the formation of tight junctions between cells, restricting the permeation of solutions and molecules into the intercellular space, and plays an important role in maintaining the integrity of the outer and basement membranes of endothelial cells, and may be involved in signal transduction.
[0003] Claudin 18 is a multi-spanning membrane protein with four transmembrane domains, two of which form the extracellular domain (loop 1 and loop 2) and two of which form the intracellular domain. Due to alternative RNA splicing, two distinct membrane protein subtypes, claudin 18.1 (Uniprot U56856) and claudin 18.2 (Uniprot U56856-2), exist in tissues. These two subtypes differ in the N-terminal transmembrane domain (amino acid residues 1–27) and the first extracellular domain (loop 1, amino acid residues 28–80). The sequence similarity of loop 1 is approximately 85%, making it possible to generate antibodies specifically targeting claudin 18.2. Claudin-18 membrane protein subtypes vary in distribution in normal tissues. Claudin-18.1 is selectively expressed in normal lung tissue, whereas claudin-18.2 is highly and specifically expressed only on the surface of well-differentiated gastric mucosal cells and is not detected in stem cell regions near the submucosa of gastric tissue. Studies have shown that claudin-18.2 is not only expressed in 70% of primary gastric cancers and their metastases, but also in many other cancers, including pancreatic cancer (50%), esophageal cancer (30%), non-small cell lung cancer (25%), breast cancer, and ear, nose, and throat tumors. Because of its widespread expression in gastrointestinal tumors, claudin-18 may be a novel tumor marker and potential therapeutic target. Summary of the Invention [Problem to be solved by the invention]
[0004] Through extensive detailed research and mass screening, the present inventors unexpectedly obtained an anti-claudin 18.2 antibody with excellent affinity and specificity, and a humanized antibody based on said antibody. The antibody of the present invention can bind to claudin 18.2 with high specificity, has high affinity, and mediates cell killing, making it suitable for use in the diagnosis and treatment of several malignant tumors, such as gastric cancer and pancreatic cancer. Based on this, the present invention was completed. [Means for solving the problem]
[0005] In one aspect, the present disclosure provides an antibody, or antigen-binding portion thereof, that binds to human claudin-18.2.
[0006] In one aspect, the present disclosure provides a nucleic acid molecule encoding an antibody or antigen-binding portion thereof according to the above aspect.
[0007] In one aspect, the present disclosure provides a carrier comprising the nucleic acid according to the above aspect.
[0008] In one aspect, the present disclosure provides a cell comprising a carrier according to the above aspect.
[0009] In the antibody or antigen-binding portion thereof according to any of the above aspects, the antibody or antigen-binding portion thereof is humanized.
[0010] In one aspect, the present disclosure provides a pharmaceutical composition or kit comprising an antibody or antigen-binding portion thereof according to any of the above aspects, or a nucleic acid encoding the antibody or antigen-binding portion thereof, and a pharmaceutically acceptable carrier.
[0011] A method for treating cancer according to one embodiment includes administering to the mammal a therapeutically effective amount of an antibody or antigen-binding fragment thereof, or a nucleic acid molecule, or a carrier, or a cell, or a pharmaceutical composition according to any of the above embodiments.
[0012] One embodiment of the invention relates to the use of an antibody or antigen-binding fragment thereof, or a nucleic acid molecule, or a carrier, or a cell, or a pharmaceutical composition according to any of the above embodiments in the preparation of a drug or kit for treating cancer in a mammal. [Brief explanation of the drawings]
[0013] [Figure 1]RT-PCR showed that the HEK293 stable transfectants expressed claudin 18.1 and claudin 18.2, respectively. Both the HEK293-claudin 18.2 stable transfectants and the control KATO III cells were able to amplify the characteristic 780-bp band specific for claudin 18.2, while the HEK293-claudin 18.1 transfectants were able to amplify only the 504-bp common fragment. [Figure 2] Figure 1 shows the results of screening high-expressing HEK293-claudin18.2 stable transfectant cell lines by FACS experiment. In the figure, black dots represent negative controls, and gray dots represent high-expressing HEK293-claudin18.2 stable transfectant cell lines. [Figure 3] This figure shows the results of screening for high-expressing NIH3T3-claudin 18.2 stable transfectants using FACS. The black line represents the negative control, and the gray shaded areas represent 3T3-claudin 18.2 stable transfectants. NO.32-H is a high-expressing 3T3-claudin 18.2 stable transfectant, NO.18-M is a medium-expressing 3T3-claudin 18.2 stable transfectant, and NO.6-L is a low-expressing 3T3-claudin 18.2 stable transfectant. [Figure 4] Specific recognition of claudin 18.2 by monoclonal antibodies. Flow cytometry (FACS) revealed that the resulting chimeric claudin 18.2 IgG1 antibody recognized only claudin 18.2-transfected HEK293-claudin 18.2 cells (Figure 4B), but did not bind to either HEK293 (Figure 4A) or HEK293-claudin 18.1 (Figure 4C). [Figure 5] This shows the change in the number of antibodies on the cell surface associated with intracellular uptake after incubating the cells with claudin 18.2 antibody at 37°C for different periods of time. [Figure 6] 1 shows the ADCC cell-killing activity of claudin 18.2 humanized antibody to KATO III cells. [Figure 7] 1 shows the CDC cell-killing activity of humanized claudin 18.2 antibodies against tumor cells. [Figure 8] Intracellular uptake of claudin 18.2 antibody. Laser confocal imaging shows that the humanized claudin 18.2 antibody (red) binds to the cell membrane, and after being internalized into the cell, a portion of it overlaps with lysosomes (green), forming a yellow spot indicated by the arrow (blue is the cell nucleus). DETAILED DESCRIPTION OF THE INVENTION
[0014] I. Definition In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the terms and laboratory operation steps related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are terms and common steps widely used in the corresponding fields. In addition, in order to better understand the present invention, the following definitions and interpretations of related terms are provided.
[0015] In one aspect, the present specification provides antibodies (e.g., monoclonal antibodies) and antigen-binding fragments thereof that specifically bind to claudin 18.2. In a specific aspect, the present specification provides anti-claudin 18.2 monoclonal antibodies that specifically bind to human claudin 18.2, and the anti-claudin 18.2 antibodies include variants of a parent antibody. In a specific aspect, the present specification provides antibodies that specifically bind to claudin 18.2 (e.g., human claudin 18.2). In a particular aspect, the present specification provides anti-claudin 18.2 antibodies that contain one or more amino acid residue modifications (e.g., 5 to 13 amino acid substitutions in the framework region of the heavy chain variable region) and maintain affinity for the antigen compared to a parent antibody without the modifications.
[0016] As used herein, the terms "about" or "approximately," unless otherwise specified, mean within plus or minus 10% of a given value or range. When applied to integers, these terms mean rounding up or down to the nearest integer within plus or minus 10% of the given value or range.
[0017] With respect to the polypeptide sequence of an antibody chain, the phrase "substantially identical" can be interpreted as an antibody chain exhibiting at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the reference polypeptide sequence. With respect to a nucleic acid sequence, the term can be interpreted as a nucleotide sequence exhibiting at least greater than 60%, and greater than 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity to the reference nucleic acid sequence.
[0018] Sequence "homology" or "identity" has a meaning commonly accepted in the art, and the disclosed techniques can be used to calculate the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions. Sequence homology can be measured along the entire length of a polynucleotide or polypeptide or along a region of the molecule. While there are many methods for measuring homology between two polynucleotides or polypeptides, the term "homology" is well known to those skilled in the art (Carrillo, H. & Lipman, D., SIAM J Applied Math 48:1073 (1988)).
[0019] "Substitutional" variants are those in which at least one amino acid residue in a native sequence has been removed and a different amino acid inserted at the same position. The substitutions can be single, where only one amino acid in the molecule is substituted, or they can be multiple, where two or more amino acids in the same molecule are substituted. Multiple substitutions can be at contiguous positions. Similarly, an amino acid can be substituted with multiple residues, in which case such a variant includes both substitutions and insertions. "Insertion" variants are those in which one or more amino acids have been inserted immediately adjacent to an amino acid at a particular position in the native sequence. "Directly adjacent to an amino acid" means linked to the α-carboxyl or α-amino functional group of that amino acid. "Deletion" variants are those in which one or more amino acids in the native amino acid sequence have been removed. Typically, deletion variants delete one or two amino acids in a particular region of the molecule.
[0020] The term "variable" in the context of antibody variable domains refers to the several portions of the related molecule that differ significantly in sequence among antibodies and are used in the specific recognition and binding of a particular antibody to its particular target. However, variability is not evenly distributed throughout the variable domains of antibodies. The variability is concentrated in three segments called complementarity-determining regions (CDRs, i.e., CDR1, CDR2, and CDR3) or hypervariable regions in both the light-chain and heavy-chain variable domains. The more highly conserved portions of the variable domains are called framework (FR) regions or sequences. Native heavy- and light-chain variable domains each contain four FR regions that primarily adopt a β-sheet configuration, connected by three CDRs, which form loops that connect, and in some cases form part of, the β-sheet structure. The CDRs in each chain are often closely connected by FR regions and, together with the CDRs from the other chain, contribute to the formation of the antibody's target-binding site (epitope or determinant). As used herein, immunoglobulin amino acid residue numbering is performed according to the immunoglobulin amino acid residue numbering system of Kabat et al., unless otherwise specified. One CDR can have the ability to specifically bind to a cognate epitope.
[0021] As used herein, an "antibody fragment" or "antigen-binding fragment" of an antibody refers to any portion of a full-length antibody that is less than full-length but contains at least a portion of the variable region of the antibody that binds to an antigen (e.g., one or more CDRs and / or one or more antibody-binding sites) and thus retains at least a portion of the binding specificity and specific binding ability of the full-length antibody. Thus, an antigen-binding fragment refers to an antibody fragment that contains an antigen-binding portion that binds to the same antigen as the antibody from which the antibody fragment is derived. Antibody fragments include antibody derivatives produced by enzymatic treatment of full-length antibodies and derivatives produced synthetically, e.g., recombinantly. Antibodies include antibody fragments. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, single-chain Fv (scFv), Fv, dsFv, diabody, Fd, and Fd' fragments, as well as other fragments, including modified fragments. The fragments may contain, for example, multiple chains linked together by disulfide bonds and / or peptide linkers. Antibody fragments generally contain at least or about 50 amino acids, usually at least or about 200 amino acids. Antigen-binding fragments are fragments that, when inserted into an antibody framework (such as by replacing the corresponding region), immunospecifically bind to the antigen (i.e., at least or at least about 10 7 ~10 8 M -1 A "functional fragment" or "anti-claudin 18.2 antibody analog" is a fragment or analog that can inhibit or substantially reduce the ability of the receptor to bind to a ligand or initiate signal transduction. As used herein, functional fragment is generally synonymous with "antibody fragment," and with respect to antibodies, refers to a fragment or analog that can inhibit or substantially reduce the ability of the receptor to bind to a ligand or initiate signal transduction, F v , F ab , F (ab’)2 It can refer to fragments such as "F v The " fragments comprise a dimer of one heavy-chain variable domain and one light-chain variable domain in non-covalent association (V H -V LIn this configuration, the three CDRs of each variable domain interact to form a V H -V L The six CDRs define a target-binding site on the surface of the dimer. Collectively, the six CDRs confer target-binding specificity to the intact antibody. However, a single variable domain (or F domain containing only three CDRs) is specific for a target. v Even half of the total number of nucleotides can be capable of recognizing and binding to the target.
[0022] As used herein, "monoclonal antibody" refers to a population of identical antibodies, meaning that each individual antibody molecule in the monoclonal antibody population is identical to the other antibody molecules. This characteristic is in contrast to the characteristics of a polyclonal population of antibodies, which contains antibodies with multiple different sequences. Monoclonal antibodies can be prepared by several well-known methods (Smith et al. (2004) J. Clin. Pathol. 57, 912-917; and Nelson et al., J Clin Pathol (2000), 53, 111-117). For example, monoclonal antibodies can be prepared by immortalizing B cells, e.g., by fusing them with myeloma cells to produce hybridoma cell lines, or by infecting B cells with a virus such as EBV. Recombinant techniques can also be used to prepare antibodies from a clonal population of host cells in vitro by transforming the host cells with a plasmid carrying an artificial sequence of nucleotides encoding the antibody.
[0023] As used herein, the term "hybridoma" or "hybridoma cell" refers to a cell or cell line (usually a myeloma or lymphoma cell) produced by fusing an antibody-producing lymphocyte with a non-antibody-producing cancer cell. As known to those skilled in the art, a hybridoma is capable of producing and continuously supplying a specific monoclonal antibody. Methods for producing hybridomas are well known in the art. When the term "hybridoma" or "hybridoma cell" is referred to, it further includes subclones and progeny of the hybridoma.
[0024] As used herein, a full-length antibody is an antibody having two full-length heavy chains (e.g., VH-CH1-CH2-CH3 or VH-CH1-CH2-CH3-CH4), two full-length light chains (VL-CL), and a hinge region, e.g., an antibody having the same domains synthetically produced as an antibody naturally produced by an antibody-secreting B cell.
[0025] The term "chimeric antibody" refers to an antibody in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, e.g., the variable region sequences are derived from a murine antibody and the constant region sequences are derived from a human antibody.
[0026] "Humanized" antibodies refer to forms of non-human (e.g., murine) antibodies that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. Preferably, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from the complementarity-determining regions (CDRs) of the recipient are substituted by residues from CDRs of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity.
[0027] During humanization, it is also possible to improve one or more binding characteristics (e.g., affinity) of an antibody by mutating amino acid residues within CDR1, CDR2, and / or CDR3 of VH and / or VL. Mutations can be introduced, for example, by PCR-mediated mutagenesis, and their effect on antibody binding or other functional properties can be assessed by in vitro or in vivo testing as described herein. Conservative mutations are generally introduced. Such mutations may be amino acid substitutions, additions, or deletions. Furthermore, mutations within a CDR typically do not exceed one or two. Thus, the humanized antibody of the present invention also covers antibodies containing one or two amino acid mutations within a CDR.
[0028] As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually contain chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.
[0029] As used herein, the terms "specifically bind" or "immunospecifically bind," with respect to an antibody or antigen-binding fragment thereof, are used interchangeably herein and refer to the ability of an antibody or antigen-binding fragment to form one or more non-covalent bonds with a cognate antigen by non-covalent interactions between the antibody and the antibody-binding site of the antigen. The antigen may be an isolated antigen or may be present in tumor cells. Typically, an antibody that immunospecifically binds (or specifically binds) to an antigen is present in an amount of about 1×10 7 M -1 Or 1 x 10 8 M -1 or higher affinity constant Ka (or 1 × 10 -7 M or 1 x 10 -8The antibody binds to the antigen with a dissociation constant (Kd) of M or less. The affinity constant can be measured by standard kinetic methods of antibody reactions, such as immunoassays, surface plasmon resonance (SPR) (Rich and Myszka (2000) Curr. Opin. Biotechnol 11:54; Englebienne (1998) Analyst. 123:1599), isothermal titration calorimetry (ITC), or other kinetic interaction measurements well known in the art (see also U.S. Pat. No. 7,229,619 for a description of exemplary SPR and ITC methods for calculating antibody binding affinity). Devices and methods for real-time detection and monitoring of binding kinetics are well known and commercially available.
[0030] As used herein, the term "compete" with respect to antibodies means that a first antibody or antigen-binding fragment thereof binds to an epitope in a manner sufficiently similar to the binding of a second antibody or antigen-binding fragment thereof, such that the resulting binding of the first antibody to its cognate epitope is detectably reduced in the presence of the second antibody compared to its absence. Alternatively, the binding of the second antibody to its epitope can also be, but need not be, detectably reduced in the presence of the first antibody. That is, a first antibody can inhibit the binding of a second antibody to its epitope, but the second antibody need not inhibit the binding of the first antibody to its respective epitope. However, if each antibody detectably inhibits the binding of the other antibody to its cognate epitope or ligand, whether at the same level, a higher level, or a lower level, the antibodies are said to "cross-compete" with each other for binding of their respective epitopes. Both competing and cross-competing antibodies are encompassed by the present invention. Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational change, or binding to a common epitope or fragment thereof), one skilled in the art will recognize, based on the teachings of the present invention, that such competing and / or cross-competing antibodies are encompassed by the present invention and applicable to the methods disclosed herein.
[0031] As used herein, the terms "polynucleotide" and "nucleic acid molecule" refer to an oligomer or polymer containing at least two linked nucleotides or nucleotide derivatives, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), usually linked via a phosphodiester bond. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, and may be cDNA.
[0032] As used herein, an isolated nucleic acid molecule is a nucleic acid molecule that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid molecule. An "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when prepared by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Exemplary isolated nucleic acid molecules according to the present specification include isolated nucleic acid molecules that encode the provided antibodies or antigen-binding fragments.
[0033] As used herein, the term "operably linked" with respect to a nucleic acid sequence, region, element, or domain indicates that the nucleic acid regions are functionally related to each other. For example, a promoter can be operably linked to a nucleic acid encoding a polypeptide such that the promoter controls or mediates transcription of the nucleic acid.
[0034] Also provided are "conservative sequence modifications" of the sequences in the sequence listings described herein, i.e., nucleotide and amino acid sequence modifications that do not eliminate the binding of an antigen to an antibody encoded by the nucleotide sequence or containing the amino acid sequence. These conservative sequence modifications include conservative nucleotide and amino acid substitutions, and nucleotide and amino acid additions and deletions. For example, modifications can be introduced into the sequence listings described herein by standard techniques well known in the art (e.g., site-directed mutagenesis and PCR-mediated mutagenesis). Conservative sequence modifications include conservative amino acid substitutions, in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, predicted non-essential amino acid residues in anti-claudin-18.2 antibodies are preferably replaced with another amino acid residue from the same side chain family. Methods for identifying conservative nucleotide and amino acid substitutions that do not eliminate antigen binding are well known in the art (see, e.g., Blommell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al., Protein Eng. 12(10):879-884 (1999); and Burks et al., Proc. Natl. Acad. Sci. USA 94:412-417 (1997)).
[0035] Alternatively, in another embodiment, mutations can be introduced randomly along all or part of the sequence encoding an anti-claudin 18.2 antibody, e.g., by saturation mutagenesis, and the resulting modified anti-claudin 18.2 antibodies can be screened for improved binding activity.
[0036] As used herein, "expression" refers to the process of producing a polypeptide by transcription and translation of a polynucleotide. The expression level of a polypeptide can be assessed using any method known in the art, including, for example, methods for measuring the amount of polypeptide produced from a host cell. Such methods can include, but are not limited to, quantification of polypeptide in a cell lysate by ELISA, Coomassie blue staining after gel electrophoresis, Lowry protein assay, and Bradford protein assay.
[0037] As used herein, a "host cell" is a cell for receiving, maintaining, replicating, and amplifying a carrier. The host cell can further be used to express the polypeptide encoded by the carrier. When the host cell divides, the nucleic acid contained in the carrier is replicated, amplifying the nucleic acid. The host cell can be a eukaryotic cell or a prokaryotic cell. Suitable host cells include, but are not limited to, CHO cells, various COS cells, HeLa cells, and HEK cells, such as HEK293 cells.
[0038] As used herein, a "carrier" refers to a replicable nucleic acid that can express one or more heterologous proteins when transformed into a suitable host cell. Reference to a carrier generally includes a carrier into which a nucleic acid encoding a polypeptide or a fragment thereof can be introduced by restriction digestion and ligation. Reference to a carrier further includes a carrier containing a nucleic acid encoding a polypeptide. A carrier is used to introduce a nucleic acid encoding a polypeptide into a host cell for amplification of the nucleic acid or for expression / display of the polypeptide encoded by the nucleic acid. Carriers generally remain episomal, but may also be designed to cause a gene or a portion thereof to be integrated into a genomic chromosome. Also contemplated are carriers that are artificial chromosomes, such as yeast artificial chromosomes and mammalian artificial chromosomes. The selection and use of such vehicles are well known to those skilled in the art.
[0039] As used herein, carrier further includes a "viral carrier" or "viral carrier." A viral carrier is an engineered virus operably linked to an exogenous gene so as to transfer the exogenous gene into a cell (as a vehicle or shuttle).
[0040] As used herein, "expression carrier" includes a carrier capable of expressing DNA, said DNA being operably linked to regulatory sequences, e.g., promoter regions, that affect expression of the DNA fragment. Such additional segments may include promoter and terminator sequences, and may optionally include one or more origins of replication, one or more selectable markers, enhancers, polyadenylation signals, etc. Expression carriers are generally derived from plasmid or viral DNA or may contain elements of both. Thus, expression carriers refer to recombinant DNA or RNA constructs, e.g., plasmids, phages, recombinant viruses, or other carriers that result in expression of cloned DNA upon introduction into a suitable host cell. Suitable expression carriers are well known to those skilled in the art and include expression carriers that are replicable in eukaryotic and / or prokaryotic cells, as well as expression carriers that remain episomal or that integrate into the host cell genome.
[0041] As used herein, "treating" an individual having a disease or in a disease state means that the individual's symptoms are partially or totally ameliorated or remain unchanged following treatment. Thus, treatment includes prophylaxis, treatment, and / or cure. Prevention refers to preventing potential disease and / or preventing worsening of symptoms or progression of disease. Treatment further includes any pharmaceutical use of any of the provided antibodies or antigen-binding fragments thereof and compositions provided herein.
[0042] As used herein, "therapeutic benefit" means the benefit obtained by treating an individual, which is a change, usually an improvement or amelioration, of the symptoms of a disease or disease state, or a cure of the disease or disease state.
[0043] As used herein, a "therapeutically effective amount" or "therapeutically effective dose" refers to an amount of a drug, compound, substance, or composition containing a compound that is at least sufficient to achieve a therapeutic effect after administration to a subject, and thus is the amount necessary to prevent, cure, ameliorate, suppress, or partially suppress the symptoms of a disease or condition.
[0044] As used herein, a "prophylactically effective amount" or "prophylactically effective dose" refers to the amount of a drug, compound, substance, or composition containing a compound that, when administered to a subject, has an intended prophylactic effect, such as preventing or delaying the occurrence or recurrence of a disease or condition, or reducing the likelihood of the occurrence or recurrence of a disease or condition. A complete prophylactically effective dose need not be achieved by administration of a single dose, but may be achieved only when a series of doses are administered. Thus, a prophylactically effective amount can be administered in one or more administrations.
[0045] As used herein, the term "patient" refers to a mammal, for example, a human.
[0046] II. MODE FOR CARRYING OUT THE INVENTION In one aspect, the present disclosure provides amino acid sequences of SEQ ID NOs: 2-4, 12-14, 22-24, 32-34, 42-44, 52-54, 62-64, 72-74, 82-84, 92-94, 102-104, 112-114, 122-124, 132-134, 142-144, 152-154, 157-159, 162-164, 167-169, 172-174, 177-179, 182-184, 187-189, 192-194, 197-199, 202-204, 207-209, 212-214, 217-219, 222-224, 227-229, 232-234 or any variant thereof, and / or a light chain CDR selected from the amino acid sequences set forth in SEQ ID NOs: 7-9, 17-19, 27-29, 37-39, 47-49, 57-59, 67-69, 77-79, 87-89, 97-99, 107-109, 117-119, 127-129, 137-139, 147-149, 237-239, 242-244, 247-249, 252-254, 257-259, 262-264, 267-269, or any variant thereof.
[0047] The antibody or antigen-binding portion thereof according to the previous aspect may comprise a heavy chain CDR1 selected from the amino acid sequences of SEQ ID NOs: 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, 132, 142, 152, 157, 162, 167, 172, 177, 182, 187, 192, 197, 202, 207, 212, 217, 222, 227, 232 or any variant thereof; , 83, 93, 103, 113, 123, 133, 143, 153, 158, 163, 168, 173, 178, 183, 188, 193, 198, 203, 208, 213, 218, 223, 228, 233, or any variant thereof, heavy chain CDR2, amino acid sequence SEQ ID NOs: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, 124, 134, 144, 154, 159, 164, 169, 174, 179, 184 , 189, 194, 199, 204, 209, 214, 219, 224, 229, 234, or any variant thereof, and / or a light chain CDR1 selected from the amino acid sequences of SEQ ID NOs: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 237, 242, 247, 252, 257, 262, 267, or any variant thereof; and a light chain CDR3 selected from the amino acid sequences of SEQ ID NOs: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, 129, 139, 149, 239, 244, 249, 254, 259, 264, 269, or any variant thereof.
[0048] The antibody or antigen-binding portion thereof according to any of the above embodiments comprises a heavy chain variable region selected from the amino acid sequences of SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 156, 161, 166, 171, 176, 181, 186, 191, 196, 201, 206, 211, 216, 221, 226, 231, or any variant thereof, and / or a light chain variable region selected from the amino acid sequences of SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 236, 241, 246, 251, 256, 261, 266, or any variant thereof.
[0049] Nucleic acid molecules encoding the antibodies or antigen-binding portions thereof according to any of the above embodiments comprise an antibody heavy chain nucleic acid sequence selected from SEQ ID NOs: 5, 15, 25, 35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 135, 145, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, or any variant thereof, and / or an antibody light chain nucleic acid sequence selected from SEQ ID NOs: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 240, 245, 250, 255, 260, 265, 270, or any variant thereof.
[0050] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequences of SEQ ID NOs: 151, 156, 161, 166, 171, 176, 181, 186, 191, 196, 201, 206, 211, 216, 221, 226, 231, or any variant thereof, and / or a light chain variable region selected from the amino acid sequences of SEQ ID NOs: 236, 241, 246, 251, 256, 261, 266, or any variant thereof.
[0051] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 151 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 236 or any variant thereof.
[0052] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 151 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 241 or any variant thereof.
[0053] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 151 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0054] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 156 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 236 or any variant thereof.
[0055] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 156 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 241 or any variant thereof.
[0056] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 156 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0057] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 161 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 236 or any variant thereof.
[0058] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 161 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 241 or any variant thereof.
[0059] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 161 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0060] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 166 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 236 or any variant thereof.
[0061] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 166 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 241 or any variant thereof.
[0062] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 166 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0063] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 171 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 251 or any variant thereof.
[0064] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 171 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0065] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 176 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 251 or any variant thereof.
[0066] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 176 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0067] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 181 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 251 or any variant thereof.
[0068] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 181 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0069] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 186 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 251 or any variant thereof.
[0070] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 186 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0071] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 191 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 251 or any variant thereof.
[0072] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 191 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0073] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 196 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 251 or any variant thereof.
[0074] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 196 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0075] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 201 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 251 or any variant thereof.
[0076] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 201 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 256 or any variant thereof.
[0077] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 206 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 261 or any variant thereof.
[0078] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 206 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 266 or any variant thereof.
[0079] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 211 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 261 or any variant thereof.
[0080] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 211 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 266 or any variant thereof.
[0081] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 216 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 261 or any variant thereof.
[0082] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 216 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 266 or any variant thereof.
[0083] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 221 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 261 or any variant thereof.
[0084] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 221 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 266 or any variant thereof.
[0085] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 226 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 261 or any variant thereof.
[0086] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 226 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 266 or any variant thereof.
[0087] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 231 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 261 or any variant thereof.
[0088] In one aspect, the present disclosure relates to an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain variable region selected from the amino acid sequence of SEQ ID NO: 231 or any variant thereof, and / or a light chain variable region selected from the amino acid sequence of SEQ ID NO: 266 or any variant thereof.
[0089] In one specific embodiment, the present disclosure provides the amino acid sequences SEQ ID NOs: 152-154, 157-159, 162-164, 167-169, 172-174, 177-179, 182-184, 187-189, 192-194, 197-199, 202-204, 207-209, 212-214, 217-219, 222-224, 227-229, 232 The present invention provides an antibody or antigen-binding portion thereof that binds to human claudin-18.2, comprising a heavy chain CDR selected from -234 or any variant thereof, and / or a light chain CDR selected from amino acid sequences of SEQ ID NOs: 237-239, 242-244, 247-249, 252-254, 257-259, 262-264, 267-269, or any variant thereof.
[0090] In one embodiment, an antibody or antigen-binding portion thereof that binds to human claudin-18.2 comprises: (1) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 152-154, respectively, and / or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 237-239, respectively; (2) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 152-154, respectively, and / or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 242-244, respectively; (3) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 152-154, respectively; and (4) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 157-159, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 237-239, respectively; (5) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 157-159, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 242-244, respectively; (6) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 157-159, respectively. (7) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 162-164, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 237-239, respectively; (8) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 162-164, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 242-244, respectively; (9) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 162-164, respectively. (10) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 167-169, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 237-239, respectively; (11) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 167-169, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 242-244, respectively; (12) heavy chain CDR1 comprising SEQ ID NOs: 167-169, respectively;(13) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 172-174, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 252-254, respectively; (14) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 172-174, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 257-259, respectively; (15) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 177-179, respectively. (16) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 177-179, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 257-259, respectively; (17) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 182-184, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 252-254, respectively; (18) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 182-184, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 182-184, respectively; (19) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 187-189, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 252-254, respectively; (20) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 187-189, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 257-259, respectively; (21) each (21) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 192-194, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 252-254, respectively; (22) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 192-194, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 257-259, respectively; (23) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 197-199, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 252-254, respectively;(24) heavy chain CDR1, CDR2, and CDR3 sequences each comprising SEQ ID NOs: 197-199, and / or light chain CDR1, CDR2, and CDR3 sequences each comprising SEQ ID NOs: 257-259; (25) heavy chain CDR1, CDR2, and CDR3 sequences each comprising SEQ ID NOs: 202-204, and / or light chain CDR1, CDR2, and CDR3 sequences each comprising SEQ ID NOs: 252-254; (26) heavy chain CDR1, CDR2, and CDR3 sequences each comprising SEQ ID NOs: 202-204, and / or light chain CDR1, CDR2, and CDR3 sequences each comprising SEQ ID NOs: 257-259. (27) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 207-209, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 262-264, respectively; (28) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 207-209, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 267-269, respectively; (29) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 212-214, respectively, and / or SEQ ID NOs: 262-264, respectively. (30) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 212-214, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 267-269, respectively; (31) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 217-219, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 262-264, respectively; (32) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 217-219, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 217-219, respectively. (33) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 222-224, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 262-264, respectively; (34) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 222-224, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 267-269, respectively; (35) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 227-229, respectively;and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 262-264, respectively; (36) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 227-229, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 267-269, respectively; (37) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 232-234, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 262-264, respectively; (38) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 232-234, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 267-269, respectively.
[0091] An antibody or antigen-binding portion thereof that binds to human claudin-18.2 in one embodiment has a sequence identity of at least 60%, and more than 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, to an antibody or antigen-binding portion thereof in any of the above embodiments.
[0092] The nucleic acid molecule of one embodiment has a sequence identity of at least 60%, such as 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, to a nucleic acid molecule encoding an antibody or antigen-binding portion thereof of any of the above embodiments.
[0093] A carrier according to one embodiment includes the nucleic acid according to any one of the above embodiments.
[0094] The cells according to one embodiment include a carrier according to any one of the above embodiments.
[0095] A pharmaceutical composition according to one embodiment comprises an antibody or antigen-binding portion thereof according to any of the above embodiments, or a nucleic acid encoding the antibody or antigen-binding portion thereof, and a pharmaceutically acceptable carrier.
[0096] A method for treating cancer according to one embodiment includes administering to the mammal a therapeutically effective amount of an antibody or antigen-binding fragment thereof, or a nucleic acid molecule, or a carrier, or a cell, or a pharmaceutical composition according to any of the above embodiments.
[0097] One embodiment of the invention relates to the use of an antibody or antigen-binding fragment thereof, or a nucleic acid molecule, or a carrier, or a cell, or a pharmaceutical composition according to any of the above embodiments in the preparation of a drug for treating cancer in a mammal.
[0098] In any of the above embodiments, optionally the cancer is gastric cancer, optionally the antibody kills cancer cells by ADCC or CDC effect, and optionally the antibody is conjugated to another drug, e.g., a labeled or cytotoxic conjugate.
[0099] In one aspect, the present disclosure further includes kits containing the antibody, its fragment, homolog, derivative, etc., such as a labeled conjugate or cytotoxic conjugate, as well as instructions for using the antibody, conjugate, etc., for example, a conjugate that kills a specific cell type. The instructions can include instructions for using the antibody, conjugate, etc. in vitro, in vivo, or ex vivo. The antibody can be in liquid form or, typically, a lyophilized solid. The kit can include other appropriate reagents, such as buffers, reconstitution solutions, and other components required for a given application. Combinations of packaged reagents in predetermined amounts, along with instructions for that application, e.g., for therapeutic use or for performing a diagnostic assay, are contemplated. If the antibody is labeled, e.g., with an enzyme, the kit can include a substrate and a cofactor required for the enzyme (e.g., a substrate precursor that provides a detectable chromophore or fluorophore). Other additives, such as stabilizers, buffers (e.g., blocking buffers or lysis buffers), etc., can also be included. The relative amounts of the various reagents may be varied to provide a concentrated reagent solution, thereby providing the user with flexibility, space savings, reagent savings, etc. These reagents are generally provided as lyophilized dry powders and include excipients that, upon dissolution, provide a reagent solution having the appropriate concentration.
[0100] One embodiment of the use is the use of an antibody or a functional fragment thereof, or a nucleic acid molecule, or a carrier, or a cell, or a pharmaceutical composition, or a kit according to any of the above embodiments in the preparation of a reagent that mediates the cellular uptake of cell surface claudin 18.2.
[0101] The present invention further includes multivalent antibodies, including bispecific anti-claudin 18.2 antibodies, which have an effector molecule, atom, or other substance linked to the antibody that has diagnostic or therapeutic functionality. For example, the antibody can have linked to it a radioactive diagnostic label, or a radioactive cytotoxic atom or metal, or a cytotoxic substance (e.g., a ricin chain) that is used to diagnose or treat cancer in vivo.
[0102] The antibodies of the present invention may also be used in immunoassays, purification methods, and other methods that use immunoglobulins or fragments thereof, such uses being well known in the art.
[0103] Thus, the present invention further provides a composition comprising the anti-claudin 18.2 antibody or fragment thereof of the present invention, wherein the antibody is easily combined with a pharmaceutically acceptable carrier, diluent or excipient, as is common practice in the art.
[0104] The term "pharmaceutical composition" as used herein refers to a formulation of various preparations. The formulations containing a therapeutically effective amount of a multivalent antibody are in sterile liquid solution, liquid suspension or lyophilized form, and optionally contain stabilizers or excipients.
[0105] The term "cancer," as used herein, refers to or describes the physiological condition in mammals, particularly humans, typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
[0106] The antibodies of the present invention may be used as a composition to be administered alone or in combination with other active agents.
[0107] It should be understood that the therapeutic agents of the above embodiments are administered with suitable pharmaceutically acceptable carriers, excipients, and other agents that are incorporated into the formulation to improve transport, delivery, tolerance, etc. Many suitable formulations can be found in the Pharmacopoeias well known to all medicinal chemists, particularly Chapter 87 by Blaug and Seymour. These formulations may include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic)-containing carriers (e.g., Lipofectin, TM ), DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, emulsion carbowax (polyethylene glycols of different molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the above mixtures are applicable to the treatments and methods of treatment of the present invention, so long as the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable for the route of administration.
[0108] In one embodiment, the antibodies can be used as therapeutic agents. Such agents are generally used to treat, alleviate, and / or prevent diseases or conditions associated with aberrant claudin 18.2 expression, activity, and / or signaling in a subject. Treatment regimens can be implemented using standard methods by identifying a subject, such as a human patient, suffering from (or at risk of developing or progressing to) a disease or disorder associated with aberrant claudin 18.2 expression, activity, and / or signaling, such as cancer or other neoplastic disorders. Antibody preparations, preferably those with high specificity and high affinity for their target antigen, typically exhibit an effect via target binding when administered to a subject. Administration of the antibody can eliminate, suppress, or block the expression, activity, and / or signaling function of the target (e.g., claudin 18.2). Administration of the antibody can eliminate, suppress, or block binding between the target (e.g., claudin 18.2) and its naturally occurring endogenous ligand. For example, the antibody binds to a target and modulates, blocks, suppresses, reduces, inhibits, neutralizes, or otherwise prevents the expression, activity, and / or signaling of claudin 18.2. In some embodiments, an antibody having heavy and light chain CDRs can be administered to a subject to treat a disease or disorder associated with aberrant claudin 18.2 expression. In one embodiment, the disease or disorder associated with aberrant claudin 18.2 expression may be cancer.
[0109] By way of non-limiting example, diseases or disorders associated with aberrant claudin-18.2 expression, activity, and / or signaling include hematological cancers and / or solid tumors. Hematological cancers include, for example, leukemia, lymphoma, and myeloma. By way of non-limiting example, some forms of leukemia include acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), myeloproliferative disorders / neoplasms (MPDS), and myelodysplastic syndromes. By way of non-limiting example, some forms of lymphoma include Hodgkin's lymphoma, low-grade and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell types). By way of non-limiting example, some forms of myeloma include multiple myeloma (MM), giant cell myeloma, heavy chain myeloma, and light chain or Bence-Jones myeloma. Solid tumors include, for example, breast tumors, ovarian tumors, lung tumors, pancreatic tumors, prostate tumors, melanoma, colorectal tumors, lung tumors, head and neck tumors, bladder tumors, esophageal tumors, liver tumors, and kidney tumors.
[0110] Symptoms associated with cancer and other neoplastic disorders include, for example, inflammation, fever, general malaise, fever, pain, often localized inflammation, loss of appetite, weight loss, edema, headache, fatigue, rash, anemia, muscle weakness, muscle fatigue, and abdominal symptoms such as abdominal pain, diarrhea, or constipation.
[0111] In another embodiment, antibodies targeting claudin 18.2 can be used by methods well known in the art related to the localization and / or quantification of claudin 18.2 (e.g., for measuring levels of claudin 18.2 and / or claudin 18.2 in an appropriate physiological sample, for use in diagnostic methods, for use in protein imaging, etc.). In one particular embodiment, an antibody specific for claudin 18.2 or a derivative, fragment, analog, or homolog thereof and comprising an antigen-binding domain derived from the antibody is used as a pharmacologically active compound (hereinafter referred to as a "therapeutic agent").
[0112] In another embodiment, claudin 18.2 polypeptides can be isolated using antibodies specific for claudin 18.2 by standard methods, such as immunoaffinity, chromatography, or immunoprecipitation. Antibodies (or fragments thereof) targeting the claudin 18.2 protein can be used to detect the protein in biological samples. In some embodiments, claudin 18.2 can be detected in biological samples as part of a clinical trial procedure, for example, to determine the efficacy of a given therapeutic regimen. Detection can be facilitated by conjugating (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin / biotin and avidin / biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material is luminol; examples of bioluminescent materials include luciferase, fluorescein and aequorin; examples of suitable radioactive materials are 125 I, 131 I, 35 S or 3 Contains H.
[0113] In another embodiment, the antibody of the present disclosure can be used as a reagent for detecting claudin-18.2 or its protein fragments in a sample. In some embodiments, the antibody comprises a detectable label. The antibody is a polyclonal antibody, or more preferably, a monoclonal antibody. An intact antibody or a fragment thereof (e.g., Fab, scFv, or F(ab')2) can be used. The term "labeling" with respect to an antibody is intended to include direct labeling of the antibody by conjugating (i.e., physically linking) a detectable substance to the antibody, and indirect labeling of the antibody by reaction with another directly labeled reagent. Examples of indirect labeling include detecting a first antibody using a fluorescently labeled second antibody and end-labeling the antibody with biotin for detection by fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells, and biological fluids isolated from a subject, as well as tissues, cells, and fluids present within the subject's body. Thus, the term "biological sample" as used herein includes blood and blood fractions or components, including serum, plasma, or lymph. In other words, the detection methods of the above embodiments can be used to detect analyte mRNA, protein, or genomic DNA in a biological sample in vitro and in vivo. For example, in vitro techniques for detecting analyte mRNA include Northern hybridization and in situ hybridization. In vitro techniques for detecting analyte protein include enzyme-linked immunosorbent assay (ELISA), Western blot, immunoprecipitation, and immunofluorescence. In vitro techniques for detecting analyte genomic DNA include Southern hybridization. In addition, in vivo techniques for detecting analyte protein include introducing a labeled anti-analyte protein antibody into a subject's body. For example, the antibody can be labeled with a radioactive marker, and the presence or location of the radioactive marker in the subject's body can then be detected by standard imaging techniques.
[0114] The antibodies and derivatives, fragments, analogs, and homologs thereof described herein can be incorporated into pharmaceutical compositions suitable for administration. The principles and considerations involved in preparing such compositions, as well as guidance for the selection of components, are well known in the art.
[0115] Such compositions generally comprise an antibody and a pharmaceutically acceptable carrier. When antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, peptide molecules can be designed based on the variable region sequences of an antibody while retaining the ability to bind to the target protein sequence. Such peptides can be chemically synthesized and / or produced by recombinant DNA technology (see, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90:7889-7893 (1993)).
[0116] As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with drug administration. Suitable pharmaceutically acceptable carriers are described in the latest edition of Remington's Pharmaceutical Sciences, a standard reference text in this field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, glucose solution, and 5% human serum albumin. Non-aqueous carriers, such as liposomes and fixed oils, can also be used. The use of such media and agents in pharmaceutical active substances is well known in the art. Except as any conventional media or agent is incompatible with the antibody, its use in the composition is contemplated.
[0117] The pharmaceutical compositions of the above embodiments are formulated to be compatible with their intended route of administration. Examples of routes of administration include parenteral administration, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (e.g., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous administration can contain an injectable sterile diluent such as water, saline, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; an antibacterial agent such as benzyl alcohol or methylparaben; an antioxidant such as ascorbic acid or sodium bisulfite; a chelating agent such as ethylenediaminetetraacetic acid (EDTA); a buffer such as acetate, citrate, or phosphate; and an agent for adjusting tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide. Parenteral formulations can be enclosed in ampoules, disposable syringes, or multiple-dose vials made of glass or plastic.
[0118] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble herein) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable pharmaceutically acceptable carriers are physiological saline, bacteriostatic water, Cremophor EL TM(BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. The composition must be stable under the conditions of manufacture and storage and must be protected against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols (for example, mannitol, sorbitol), sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
[0119] Sterile injectable solutions can be prepared by adding the required amount of antibody to an appropriate solvent containing one or a combination (as needed) of the ingredients listed above, followed by filtered sterilization. Generally, dispersions are prepared by adding the antibody to a sterile carrier containing a basic dispersion medium and the other required ingredients selected from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preparation methods include vacuum drying and freeze-drying, which yield powders containing the active ingredient and any additional desired ingredients, which are derived from sterile-filtered solutions of the above ingredients.
[0120] For administration by inhalation, the compounds are administered in the form of an aerosol spray from pressured container, dispenser, or nebulizer, which contains a suitable propellant, such as a gas such as carbon dioxide.
[0121] Systemic administration can also be achieved by transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant appropriate to the barrier to be permeated is used in the formulation. Such penetrants are well known in the art and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, one or more of the above-mentioned antibodies can be formulated into plasters, ointments, gels, or creams well known in the art.
[0122] Additionally, the compounds can be prepared in the form of suppositories (eg, with conventional suppository bases such as cocoa butter or other glycerides) or retention enemas for rectal administration.
[0123] In one embodiment, the antibody can be prepared with a carrier that will prevent rapid elimination from the body, such as a sustained / controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparing such formulations are readily apparent to those skilled in the art.
[0124] It is particularly advantageous to prepare parenteral compositions in unit dosage form for ease of administration and uniformity of dosage.As used herein, unit dosage form refers to a physically discrete unit suitable for use as a unit dose for a subject to be treated, each unit containing a predetermined amount of one or more of the above antibodies calculated to achieve the desired therapeutic effect together with the necessary pharmaceutical carrier.The specifications of the unit dosage form in the above embodiment are determined by and directly depend on the inherent characteristics of the antibody and the specific therapeutic effect to be achieved, and the limitations inherent in the technical field of formulating such antibodies to treat individuals.
[0125] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
[0126] The formulations described herein may contain multiple antibodies described above, preferably with complementary activities that do not adversely affect each other, depending on the specific disease being treated. Alternatively or in addition, the composition may contain an agent that enhances its function, such as a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are present in appropriate combinations in amounts effective for the intended purpose. For example, they may be present together in a kit or during use.
[0127] In one embodiment, one or more of the above antibodies can be administered in combination therapy. That is, they can be administered in combination with other agents, such as therapeutic agents (used to treat pathological conditions or disorders, such as various forms of cancer, autoimmune diseases, and inflammatory diseases). The term "combined use" as used herein means that the agents are administered at about the same time, simultaneously, or sequentially. In the case of sequential administration, it is preferred that the first of the two compounds is still detectable at effective concentrations at the treatment site when administration of the second compound begins. In one case, "combined use" also means that the antibody of the present invention and the other therapeutic agent are included in a kit.
[0128] For example, combination therapy can involve the co-formulation and / or co-administration of one or more antibodies described herein with one or more additional therapeutic agents (e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and / or cytotoxic or cytostatic agents, as described in more detail below). Such combination therapy can advantageously utilize lower dosages of the administered therapeutic agents, thereby avoiding various potential toxicities or complications associated with monotherapy.
[0129] Although, for purposes of clarity and conciseness of description, features may be described herein as part of the same or separate embodiments, it will be understood that the scope of the invention may include several embodiments combining all or some of the described features. [Example]
[0130] <Preparation of anti-claudin 18.2 monoclonal antibody> Several strategies are simultaneously applied to immunize and screen Balb / c mice to obtain monoclonal antibodies that specifically bind only to claudin-18.2 and not to claudin-18.1, a distinct spliceosomal form of claudin-18. Specifically, the following strategies are used:
[0131] 1) Construction of claudin-18.2 stable transformed cell lines The plasmid gene claudin18.1-puc57-Amp (Suzhou Hongxun Biotechnology, SynbioTech) containing the full-length sequence of human claudin18.1 (UniProtKB-P56856) was synthesized. Using this plasmid as a template, the full-length fragment of human claudin18.1 (Met1-Val261) was amplified by PCR using the upstream primer 5'-ttggcaaagaattgctagatgtccaccaccacatgcc-3' and the downstream primer 5'-tgttcgggccctcctcgattacacatagtcgtgcttgg-3'. The amplified product was ligated using NEBuilder HiFi DNA Assembly Master Mix (NEB, Cat: M0530L) and then cloned into a eukaryotic expression plasmid system. Similarly, the plasmid gene claudin18.2-puc57-Amp (Suzhou Hongxun Biotechnology, SynbioTech) containing the full-length sequence of human claudin18.2 (UniProtKB-P56856-2) was synthesized. Using this plasmid as a template, the full-length fragment of human claudin18.2 (Met1-Val261) was amplified by PCR using the upstream primer 5'-ttggcaaagaattgctagatggccgtgactgcctgtc-3' and the downstream primer 5'-tgttcgggccctcctcgattacacatagtcgtgcttgg-3'. The amplified product was ligated using NEBuilder HiFi DNA Assembly Master Mix (NEB, Cat: M0530L) and then cloned into a eukaryotic expression plasmid system. The plasmids were electrotransformed into NIH3T3 and HEK293 cells, respectively, and stable expression cell lines were screened by stepwise pressure stimulation using 1–10 μg / mL Puromycin (Gibco, Cat: A1113803).
[0132] The HEK293-claudin18.1 and HEK293-claudin18.2 stable transfected cell lines were first verified by RT-PCR. Total RNA was extracted from positive clones using the Trizol RNA Extraction Kit. cDNA libraries were obtained by reverse transcription using an Oligo(dT) primer with a reverse transcription kit (SuperScript™ First-Strand Synthesis System, Cat. 18080051). Because the two splice fragments of claudins, claudin18.1 and claudin18.2, differ in the region from the N-terminus to the first extracellular domain (Loop 1), primers KNB14 (5'-tgtgcgccaccatggccgtg-3') and KNB15 (5'-tggaaggataagattgtacc-3') were designed to amplify the 504-bp region from Loop 1 to the C-terminus of claudin18.1 and claudin18.2. Primer KNB16 (5'-tgggtgccattggcctcctg-3') was designed to specifically bind to the N-terminus of claudin 18.2, but not to the N-terminal region of claudin 18.1. Only the full-length fragment (780 bp) from the N-terminus to the C-terminus of claudin 18.2 was amplified. KATO III cells (ATCC HTB-103), which express claudin 18.2, served as a positive control. The results are shown in Figure 1. RT-PCR demonstrated that HEK293 stable transfected cell lines express claudin 18.1 and claudin 18.2, respectively. Both the HEK293-claudin 18.2 stable transfected cell line and the control KATO III cells were able to amplify the characteristic 780 bp band specific for claudin 18.2, while HEK293-claudin 18.1 only amplified the 504 bp common fragment.
[0133] The constructed stable transfected cell lines, HEK293-claudin18.2 cells and NIH3T3-claudin18.2 cells, were digested, collected, washed twice with PBS, and 100 μL of the first antibody, rabbit anti-claudin18.2 (Abcam, EPR19202, product code: ab222512), diluted 1:200 per tube was added. The cells were incubated at 4°C for 60 minutes. The excess first antibody solution was washed off with 0.5% BSA / PBS. 50 μL of the second antibody, goat anti-rabbit IgGFc-AF647 (Jackson ImmunoResearch, product code: 111-606-046), was added and incubated at 4°C for 45 minutes. The excess second antibody was then washed off with 0.5% BSA / PBS. Finally, the cells were resuspended in 100 μL of PBS and immediately analyzed by flow cytometry. The results are shown in Figures 2 and 3.
[0134] Figure 2 shows the results of a FACS experiment detecting HEK293-claudin18.2 stable transfected cell lines transfected with the full-length claudin18.2 gene. In the figure, black dots represent untransfected HEK293 cells, and gray dots represent HEK293-claudin18.2 stable transfected cell lines. HEK293 cells do not express claudin18.2, while the HEK293-claudin18.2 stable transfected cell lines highly express claudin18.2 on their cell membrane surfaces.
[0135] Figure 3 shows the results of a FACS experiment to detect stable NIH3T3-claudin18.2 transfectants with high claudin18.2 expression. The black line represents the negative control, and the gray shaded areas represent 3T3-claudin18.2 transfectants. NO.32-H is a 3T3-claudin18.2 transfectant with high claudin18.2 expression, NO.18-M is a 3T3-claudin18.2 transfectant with moderate claudin18.2 expression, and NO.6-L is a 3T3-claudin18.2 transfectant with low claudin18.2 expression.
[0136] The expanded positive stable transfectants are collected and cryopreserved, and the NIH3T3-claudin18.2 stable transfectant cell line is used for animal immunization.
[0137] 2) Preparation of anti-claudin 18.2 monoclonal antibodies from hybridomas Six to eight-week-old female Balb / c mice were immunized with 3T3-claudin 18.2 stably transfected cells or a plasmid encoding claudin 18.2, or alternately. For cell immunizations, 1 × 10 cells were used each time. 6 3T3-claudin18.2 stable transfectants were mixed with complete or incomplete Freund's adjuvant and injected into the thigh and footpad, followed by re-immunization at different sites two weeks later. For DNA immunization, 20 μg of plasmid was mixed with 1 μg of CpG and injected directly into the abdomen of the mice using a gene gun (Biorad) at 40 psi. Mice were immunized once a week. Three days before fusion preparation, 1 × 10 high-expressing HEK293-claudin18.2 stable transfectants were transfected into the mice. 6 The cells were injected into the tail vein at a concentration of 50 μL per mouse for shock immunization. Three days later, the mice were sacrificed, and the popliteal, inguinal, and iliac lymph nodes were collected and ground with DMEM to obtain a B cell-rich suspension. The mouse spleens were removed, ground with DMEM, and centrifuged to obtain a spleen cell suspension. An appropriate amount of lymph node and spleen cell suspension was mixed with SP2 / 0 and subjected to cell fusion using an electrofusion device.
[0138] 3) Construction of an anti-claudin 18.2 phage antibody library Total RNA was extracted from cell suspensions of collected mouse spleens and peripheral lymph nodes using a Trizol RNA extraction kit. Reverse transcription was performed using a reverse transcription kit (SuperScript First-Strand Synthesis System, part number 18080051) with light- and heavy-chain-specific primers to obtain antibody light- and heavy-chain cDNA libraries, respectively. Using the cDNA as a template, antibody light- and heavy-chain variable region fragments were amplified by PCR using light- and heavy-chain variable region primers. These fragments were then restriction-enzyme cloned into phage plasmid carriers containing the human antibody light-chain constant region Ckappa or the human IgG1 heavy-chain constant region CH1 to form chimeric light- and heavy-chain libraries, respectively. The antibody fragments in the light-chain library were double-cleaved with BspQI and SfiI and then ligated to the heavy-chain library to form a mouse chimeric Fab phage display library based on the filamentous phage M13. The library size was 1.2 x 10 10 0.8 mL of phage (titer approximately 1 x 10 13 1x10 / mL) and 200 μL of 5% BSA / PBS were mixed, and then 1x10 7 Add 1x10 HEK293-claudin 18.1 cells, incubate in ice for 1 hour, and centrifuge at 1000 rpm for 10 minutes. Collect the supernatant and separate 1x10 cells into 1x10 cells. 6 HEK293-claudin 18.2 cells were mixed, incubated on ice for 1 hour, centrifuged at 1000 rpm for 3 minutes, the supernatant discarded, and 1 mL of 1% BSA / PBS was added. The mixture was washed 5-10 times. 1 mL of 100 mM TEA (triethylamine)-lysed cells was added and allowed to stand at room temperature for 10 minutes. 0.5 mL of 1 M Tris-HCl (pH 7.5) was added to neutralize the mixture. 10 mL of TG1 E. coli cells in the logarithmic growth phase were infected with the mixture and allowed to stand at 37°C for 30 minutes. Phages were recovered, titered, and then subjected to further screening according to conventional molecular biology procedures. [Example]
[0139] <Screening of anti-claudin 18.2 specific antibodies and sequence acquisition> Live cell pre-staining was performed as specified with Cell Tracker Green CMFDA Dye (Thermo, part number C2925) at 5 μM, 0.5 μM, and 0 μM for HEK293-claudin18.1, HEK293-claudin18.2, and HEK293, respectively. After washing the dye, the cells were mixed 1:1:1 and plated in a 96-well plate (2 x 10 5 The cells were added to the wells (100 μL per well) and combined with hybridoma supernatant or bacterial-induced supernatant. After incubation on ice for 1 hour, AlexaFluro647-labeled secondary antibodies (anti-mouse IgG Fc or anti-human IgG F(ab)'2) (Jackson ImmunoResearch) were added and incubated on ice for 45 minutes. After washing, 100 μL of PBS-resuspended cells were added per well. A flow cytometer (iQue Screener) was then prepared. Three distinct cell populations were identified based on fluorescence intensity in the FL2 channel, and the binding status of the test antibody to each cell population was monitored in the FL4 channel. The screened antibodies specifically bound with high affinity to HEK293-claudin18.2 stable transfectants, but did not bind to HEK293-claudin18.1 stable transfectants or HEK293 cells. A total of 320 clones that could bind to claudin 18.2 but not to claudin 18.1 were screened from hybridoma cells by FACS detection, and after three rounds of panning, 62 clones that could bind to claudin 18.2 with high affinity but not to claudin 18.1 were screened from the phage Fab library.
[0140] Plasmids were extracted from positive clones screened from the phage library and sequenced. The variable region sequences were then cloned into heavy and light chain constant region carriers for full-length IgG expression. Positive hybridoma cells were digested with 1 mL of TRNzol, and total RNA was extracted using the guanidine isothiocyanate method. First-strand cDNA was synthesized using this as a template, and the corresponding variable region DNA sequences were then amplified using the first-strand cDNA as a template. After sequencing the amplification products, the heavy and light chain variable region sequences of the candidate hybridomas were obtained (as follows).
[0141] Clone 8C11: SEQ ID NOs: 1-10 Heavy chain VH <----------FR1----------> CDR1 <----FR2-----> CDR2 <---------- QVQLQQSGAELVKPGASVKLSCKAS GYTFTTFGIN WVRQRPEQGLEWIG WIFPGDGSIKYNEKFKG KATLTTDKSSS ------FR3------------> CDR3 <---FR4---> TAYMQISSLTSEDSAVYFCAR FYYGNSFVS WGQGTLVTVSA Nucleic acid sequence CAGGTTCAGCTGCAGCAGTCTGGAGCTGAACTGGTAAAGCCTGGGGCTCAGTGAAGTTGTCCTGCAAGGCTTCTGGCTACACATTCACAACTTTTGGTATAAACTGGGTGAGGCAGAGGCCTGAACAGGGACTTGAATGGATTGGATGGATTTTTCCTGGAGATGGTAGTATTAAG TACAATGAGAAGTTCAAGGGCAAGGCCACACTGACTACAGACAAATCCTCCAGTACAGCCTACATGCAGATCAGCAGTTTGACATCTGAGGACTCGGCTGTCTATTTCTGTGCAAGGTTCTACTATGGTAACTCCTTTGTTTCCTGGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <--------------- DIVMTQSPSSLAVTAGEKVTMTC KSSQSLLNSGNQKNYLT WYQQRPGQPPKLLLY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> ALTITSVQAEDLAVYYC QNDYTYPFT FGSGTKLEIK Nucleic acid sequence GACATTGTGATGACACAGTCTCCATCCTCCCTGGCTGTGACTGCAGGAGAGAAGGTCACTATGACCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACCTGGTACCAACAGAGACCAGGGCAGCCTCCTAAACTTTTGCTCTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCGCTCTCACCATCACCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGATTATACTTATCCATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAA Clone 9A8: SEQ ID NOs: 11-20 heavy chain <----------FR1----------> CDR1 <----FR2-----> CDR2 <--------- QVQLQQSGREVVRPGTSVKVSCKPS GYAFTNYLID WVKQRPGQGLEWIG GINPGSGDTVYNEKFKA KATLTADKSSM ------FR3------------> CDR3 <---FR4---> TANMQLSSLTSDDSAVYFCAR RVRGNSFDS WGQGTLVTVSA Nucleic acid sequence CAGGTCCAGCTGCAGCAGTCTGGACGTGAGGTGGTAAGGCCTGGGACTTCAGTGAAGGTGTCCTGCAAGCCTTCTGGATACGCCTTCACTAATTACTTGATAGACTGGGTAAAACAGAGGCCTGGACAGGGCCTTGAGTGGATTGGAGGGATTAATCCTGGAAGTGGTGACACTGTGTACAATGAGAAGTTCAAGGCCAAGGCAACACTGACTGCAGACAAATCCTCCATGACTGCCAACATGCAGCTCAGCAGCCTGACATCTGATGACTCTGCGGTCTATTTCTGCGCAAGAAGGGTCCGTGGTAATTCGTTTGATTCCTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIQMTQSPSSLTVTAGEKVTMSC KSSQSLLNSGNQRNYLT WYQQKTGQPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTINSVQAEDLAVYYC QNNYYYPLT FGAGTKLEIK Nucleic acid sequence GACATTCAGATGACCCAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAGGAACTACTTGACCTGGTACCAGCAGAAAACAGGGCAGCCTCCTAAACTGTTGATCTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACTGATTTCACTCTCACCATCAACAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATAATTATTATTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAAATAAAA Clone 9C9: SEQ ID NO: 21 - 30 Heavy chain <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- EVQLKESGPGLVAPSQSLSITCTVS GFSLTNYGVS WIRQPPGKGLEWLG AIWAGGNTNYNSALMS RLSIRKDNSKSQ ------FR3-----------> CDR3 <---FR4---> VFLKMNSLQTDDTAMYYCAR VGYGNSFAN WGQGTLVTVSA Nucleic acid sequence GAGGTCCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCATCACTTGCACTGTCTCTGGGTTTTCATTGACCAACTATGGTGTTTCCTGGATTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCTGGGAGCAATATGGGCTGGTGGAAACACAAATTATAATTCGGCTCTCATGTCCAGACTGAGCATCAGGAAAGACAATTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTCCAAACTGATGACACAGCCATGTACTACTGTGCCAGAGTAGGGTATGGTAACTCGTTTGCTAACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGEKVTLSC KSSQTLLNSGNQKNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNNYFYPLT FGAGTRLEIK Nucleic acid sequence GACATTGTGATGACACAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTCTGAGCTGCAAGTCCAGTCAGACTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACGTGGTACCAGCAGAAACCAGGGCAGCCTCCTAAACTGTTGATCTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGCGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATAATTATTTTTATCCGCTCACGTTCGGTGCTGGGACCAGACTGGAAATAAAA Clone 9D12: SEQ ID NOs: 31-40 heavy chain <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- EVQLQQSGREVVRPGTSVKVSCKPS GYAFTNYLID WVKQRPGQGLEWIG GINPGSGDTVYNERFKD KATLTADKSSS ------FR3-----------> CDR3 <---FR4---> SANMQLSSLTSDDSAVYFCAR RVRGNSFDS WGQGTLVTVSA Nucleic acid sequence GAGGTCCAGCTGCAGCAGTCTGGACGTGAGGTGGTAAGGCCTGGGACTTCAGTGAAGGTGTCCTGCAAGCCTTCTGGATACGCCTTCACTAATTACTTGATAGACTGGGTTAAACAGAGGCCTGGACAGGGCCTTGAGTGGATTGGAGGGATTAATCCTGGAAGTGGTGACACTGTGTACAATGAGAGGTTCAAGGACAAGGCAACACTGACTGCAGACAAATCCTCCAGCTCTGCCAACATGCAGCTCAGCAGCCTGACATCTGATGACTCTGCGGTCTATTTCTGCGCAAGAAGGGTCCGTGGTAATTCGTTTGATTCCTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGQKVTMSC KSSQSLLNSGNQKNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFTGSGSGKDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVFYC QNNYFYPLT FGAGTKLELK Nucleic acid sequence GACATTGTGATGACTCAGTCTCCATCCTCCCTAACTGTGACAGCAGGACAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACCTGGTACCAGCAGAAACCGGGGCAGCCTCCTAAACTGTTGATCTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGGTCTGGAAAAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTTTTACTGTCAGAATAATTATTTTTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA Clone 13A8: SEQ ID NOs: 41 - 50 Heavy chain <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- EVKLVESGGGLVRPGGSLKVSCAAS GITFSRYAIS WVRQTPEKRLEWVA TISSGDSYTYYLDSVK GRFTISRDDAKN ------FR3-----------> CDR3 <---FR4---> TLYLQMSSLRSEDTAMYYCGR LGYGNAMDY WGQGTSVTVSS Nucleic acid sequence GAGGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAGGCCTGGAGGGTCCCTGAAAGTGTCCTGTGCAGCCTCTGGAATCACTTTCAGTCGCTATGCCATATCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACTATTAGTAGCGGTGATAGTTACACCTACTATTTGGACAGTGTGAAGGGGCGATTCACCATCTCCAGAGACGATGCCAAGAACACCCTGTATCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGGAAGACTGGGGTATGGTAATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- NIMMTQSPSSLTVTAGEKVTMSC KSSQSLLNSGNQKNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNDYSYPLT FGAGTKLEIK Nucleic acid sequence AACATTATGATGACACAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACCTGGTACCAGCAGAAACCAGGGCAGCCTCCTAAACTGTTGATCTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGATTATAGTTATCCTCTCACGTTCGGTGCTGGGACCAAGCTGGAAATCAAA Clone 14H11: SEQ ID NOs: 51-60 heavy chain <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- EVQLVESGGGLVKPGGSLKLSCAVS GFTINNYGMS WVRQTPEKRLEWVA TIIGGGSSTYYPDSLK GRFTISRDNAKN ------FR3------------> CDR3 <---FR4---> NLYLQMSSLRSEDTALYYCVR LYFGNSFAY WGQGTLVTVSA Nucleic acid sequence GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGTCTCTGGATTCACTATCAATAACTATGGCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACCATTATTGGTGGTGGTAGTTCCACCTACTATCCTGACAGTTTGAAGGGGCGATTCACCATCTCCAGAGACAATGCCAAGAACAACCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCTTGTATTACTGTGTAAGACTCTACTTTGGTAACTCCTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGEKVTVSC KSSQSLSNSGNQRNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNNYFYPLT FGAGTKLELK Nucleic acid sequence GACATTGTGATGACTCAGTCTCCATCCTCTCTGACTGTGACAGCAGGAGAGAAGGTCACTGTGAGCTGCAAGTCCAGTCAGAGTCTGTCAAACAGTGGAAATCAAAGGAACTACTTGACCTGGTACCAGCAGAAACCAGGGCAGCCTCCTAAACTGTTGATCTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATAATTATTTTTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA Clone 15A7: SEQ ID NO: 61 - 70 Heavy chain <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLQQSGAELVKPGYSVKLSCKAS GYTFTNFGIN WVRQRPEKGLEWIG WIFPGDGTTKYNENFK GKATLTTDKSSS ------FR3-----------> CDR3 <---FR4---> TAYMQLSRLTSEDSAVYFCAR FYYGNSFVN WGQGTLVTVSA Nucleic acid sequence CAGGTTCAGCTGCAACAGTCTGGAGCTGAACTGGTCAAGCCTGGGTATTCAGTGAAGTTGTCCTGCAAGGCTTCTGGCTACACCTTCACAAATTTTGGTATAAACTGGGTGAGGCAGAGGCCTGAAAAGGGACTTGAGTGGATTGGATGGATTTTTCCTGGAGATGGCACTACTAAATACAATGAGAACTTCAAGGGTAAGGCCACACTGACAACAGACAAATCCTCCAGCACAGCCTACATGCAGCTCAGCAGGCTGACATCTGAAGACTCTGCTGTCTATTTCTGTGCAAGGTTCTACTACGGTAACTCCTTTGTTAACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGEKVTLSC KSSQTLLNSGNQKNYLT WYQQKPGQPPKLLIH WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNNYFYPLT FGAGTKLEIK Nucleic acid sequence GACATTGTGATGACACAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTCTGAGCTGCAAGTCCAGTCAGACTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACGTGGTACCAGCAGAAACCGGGGCAGCCTCCTAAACTGTTGATCCACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATAATTATTTTTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAAATCAAA Clone 15D11: SEQ ID NOs: 71-80 heavy chain <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- QVQLQQSGPGLVAPSQSLSITCTVS GFSLTNYGVS WIRQPPGKGLEWLG AIWAGGNTNYNSALMS RLSIRKDNSKQ ------FR3----------> CDR3 <---FR4---> VFLKMNSLQTDDTAMYYCAR VGYGNSFAN WGQGTLVTVSA Nucleic acid sequence CAGGTCCAGCTGCAGCAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCATCACTTGCACTGTCTCTGGGTTTTCATTGACCAACTATGGTGTTTCCTGGATTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCTGGGAGCAATATGGGCTGGTGGAAACACAAATTATAATTCGGCTCTCATGTCCAGACTGAGCATCAGGAAAGACAATTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTCCAAACTGATGACACAGCCATGTACTACTGTGCCAGAGTAGGGTATGGTAACTCGTTTGCTAACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGEKVTMSC KSSQSLLNSGNLRNYLT WYQQKPGRPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNNYFYPLT FGAGTKLELK Nucleic acid sequence GACATTGTGATGACACAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCTAAGGAACTACTTGACCTGGTACCAGCAGAAACCAGGGCGGCCTCCTAAACTGTTGATCTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATAATTATTTTTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA Clone 15F9: SEQ ID NO: 81 - 90 Heavy chain <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- EIQLVQSGPELKKPGETVKISCKAS GYTFTNYGIN WVKQAPGKGLKWMG WINPNTGETTYAEEFK GRFALSWKTSAS ------FR3-----------> CDR3 <---FR4---> TAYLQINNLKNEDTATYFCAR LYYGNRFDY WGQGTTLTVSS Nucleic acid sequence GAGATCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTCAAGATCTCCTGCAAGGCTTCTGGATATACCTTTACAAACTATGGAATAAACTGGGTGAAGCAGGCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGGATAAACCCCAACACTGGAGAAACAACATATGCTGAAGAGTTCAAGGGACGGTTTGCCCTCTCTTGGAAAACCTCTGCCAGCACTGCCTATTTGCAGATCAACAACCTCAAAAATGAGGACACGGCTACATATTTCTGTGCAAGACTCTACTATGGTAATCGATTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGEKVTMSC KSSQSLLNSGNQRNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNAYYYPLT FGAGTKLEIK Nucleic acid sequence GACATTGTGATGACACAGTCTCCCTCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTATTAAACAGTGGAAATCAAAGGAACTATTTGACCTGGTACCAGCAGAAGCCAGGGCAGCCTCCTAAACTATTGATCTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGCCAGAATGCTTATTATTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAAATCAAA Clone 18A9: SEQ ID NOs: 91-100 heavy chain <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- QVQLQQSGREVVRPGTSVKVSCKPS GYAFTNYLID WVKQRPGQGLEWIG GINPGSGDTVYNEKFK AKATLTADKSSM ------FR3------------> CDR3 <---FR4---> TANMQLSSLTSDDSAVYFCAR RVRGNSFDS WGQGTLVTVSA Nucleic acid sequence CAGGTGCAGCTGCAGCAGTCTGGACGTGAGGTGGTAAGGCCTGGGACTTCAGTGAAGGTGTCCTGCAAGCCTTCTGGATACGCCTTCACTAATTACTTGATAGACTGGGTAAAACAGAGGCCTGGACAGGCCTTGAGTGGATTGGAGGGATTAATCCTGGAAGTGGTGACACTGTG TACAATGAGAAGTTCAAGGCCAAGGCAACACTGACTGCAGACAAATCCTCCATGACTGCCAACATGCAGCTCAGCAGCCTGACATCTGATGACTCTGCGGTCTATTCTGCCAAGAAGGGTCCGTGGTAATTCGTTTGATTCCTGGGGCCAAGGACTCTGGTCACTGTCTCTGCA Light weight <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMSQSPSSLTVTAGEKVTMSC KSSQSLLNSGNQKNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFTGSGSGKDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLALYYC QNNYFYPLT FGAGTKLELK nucleic acid sequence GACATTGTGATGTCACAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACCTGGTACCAGCAGAAACCAGGGCAGCCTCCTAAATTGTTGATCTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAAAAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCACTTTATTACTGTCAGAATAATTATTTTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA Clone 18G5: SEQ ID NOs: 101-110 heavy chain <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- EVQLQQSGREVVRPGTSVKVSCKPS GYAFTNYLID WVKQRPGQGLEWIG GINPGSGDTVYNEKFK AKATLTADKSSM ------FR3-----------> CDR3 <---FR4---> TTNMQLSSLTSDDSAVYFCAR RVRGNSFDS WGQGTLVTVSA Nucleic acid sequence GAGGTCCAGCTGCAGCAGTCTGGACGTGAGGTGGTAAGGCCTGGGACTTCAGTGAAGGTGTCCTGCAAGCCTTCTGGATACGCCTCACTAATTACTTGATAGACTGGGTAAAACAGAGGCCTGGACAGGGCCTTGAGTGGATTGGAGGGATTAATCCTGGAAGTGGTGACACTGTG TACAATGAGAAGTTCAAGGCCAAGGCAACACTGACTGCAGACAAATCCTCCATGACTACCAACATGCAGCTCAGCAGCCTGACATCTGATGACTCTGCGGTCTATTTCTGCGCAAGAAGGGTCCGTGGTAATTCGTTTGATTCCTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVRAGEKVTMTC KSSQSLFNSGNQRNYLT WYQQKPGQPPKLLLY Water GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLSISSVQAEDLAVYYC QNVYFYPLTF GAGTKLEIK Nucleic acid sequence GACATTGTGATGACACAGTCTCCATCCTCCCTGACTGTGAGAGCAGGAGAGAAGGTCACTATGACCTGCAAGTCCAGTCAGAGTCTGTTTAACAGTGGAAATCAAAGGAACTACTTGACCTGGTACCAGCAGAAACCAGGGCAGCCTCCTAAACTTTTGCTCTACTGGGCAACCGCTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGTTCTGGAACAGATTTCACTCTCTCCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGTTTATTTTTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAAATAAAA Clone 18D10: SEQ ID NO: 111-120 Heavy chain VH <----------FR1----------> CDR1 <----FR2-----> CDR2 <---------- DVQLQESGPGLVKPSQSLSLTCTVT GYSITSNYAWN WIRQFPGNKLEWMG YINYSGNTNYNPSLKS RISITRDTSKN ------FR3-----------> CDR3 <---FR4---> QFFLQLNSVTAEDTATYYCAT SYYGNSFIY WGQGTLVTVSA Nucleic acid sequence GATGTGCAGCTTCAGGAGTCGGGACCTGGCCTGGTGAAACCTTCTCAGTCTCTGTCCCTCACCTGCACTGTCACTGGCTACTCAATCACCAGTAATTATGCCTGGAACTGGATCCGACAGTTTCCAGGAAACAAACTAGAGTGGATGGGCTACATAAACTACAGTGGGAACACTAACTATAACCCATCTCTCAAAAGTCGAATCTCTATCACTCGAGACACATCCAAGAACCAGTTCTTCCTGCAGTTGAATTCTGTGACTGCTGAGGACACAGCCACATATTATTGTGCAACCTCCTATTATGGTAATTCCTTTATTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <--------------- DIVMTQSPSSLTVTAGEKVTMSC KSSQSLLNSGNQKNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNAYSFPWT FGGGTKLEIK Nucleic acid sequence GACATTGTGATGACACAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACCTGGTACCAGCAGAAACCAGGGCAGCCTCCTAAACTGTTGATCTACTGGG CATCCACTAGGGAGTCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGCTTATAGTTTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA Clone 19B2: SEQ ID NOs: 121-130 heavy chain <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- QVQLQQSGAELVKPGTSVKLSCKAS GYSFTTYGLN WVRQRPKQGLEWIG WIFPGDGNVNYNEKFQ GQATLTTDKSSS ------FR3------------> CDR3 <---FR4---> TAYMQLSRLTSEDSAVYFCAR FYYGNSLNY WGQGTLVTVSA Nucleic acid sequence CAGGTCCAGCTGCAGCAGTCTGGAGCTGAACTGGTAAAGCCTGGGACTTCAGTGAAGTTGTCCTGCAAGGCTTCTGGCTACTCCTTCACAACCTATGGTCTAAACTGGGTGAGGCAGAGGCCTAAAACAGGGACTTGAGTGGATTGGATGGATTTTCCCTGGAGATGGTAATGTTAAC TACAATGAGAAATTTCAGGGCCAGGGCCACACTGACTACAGACAAATCCTCCAGCACAGCTACATGCAGCTCAGCAGGCTGCATCTGAGGACTCTGCTGTCTTATTCTGTGCAAGGTTTTATTACGGTAACTCCTTAAATTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light weight <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGEKVTMSC KSSQSLLNSGNLRNYLT WYQQKPGRPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNNYFYPLT FGAGTKLEIK nucleic acid sequence GACATTGTGATCGACCCAGTTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCTAAGGAACTACTTGACCTGGTACCAGCAGAAAACCAGGGCGGCCTCCTAAACTGTTGATCTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATAATTATTTTTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAAATCAAA Clone 25A5: SEQ ID NOs: 131-140 heavy chain <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- EVQLKESGPGLVAPSQSLSITCTVS GFSLTNYGVS WIRQPPGKGLEWLG AIWAGGNTNYNSALMS RLSIRKDNSKSQ ------FR3------------> CDR3 <---FR4---> VFLKMNSLQTDDTAMYYCAR VGYGNSFAN WGQGTLVTVSA Nucleic acid sequence GAGGTCCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCATCACTTGCACTGTCTCTGGGTTTTCATTGACCAACTATGGTGTTTCCTGGATTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCTGGGAGCAATATGGCTGGGTGGAAACACAAATT ATAATTCGGCTCTCATGTCCAGACTGAGCATCAGGAAAGACAATTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTCCAAACTGATGACACAGCCATGTACTACTGTGCCAGAGTAGGGTATGGTAACTCGTTGCTAACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light chain <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGEKVTMSC KSSQSLLNSGNQRNYLT WYQQKPGQPPKLLIY WASTRES GIPDRFIGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDVSVYYC QNNYIFPLT FGAGTKLEIK Nucleic acid sequence GACATTGTGATGACACAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAGGAACTACTTGACCTGGTACCAGCAGAAACCAGGGCAGCCTCCTAAACTGTTGATCTACTGGG CATCCACTAGGGAATCTGGGATCCCTGATCGCTTCATAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACGTGTCAGTTTATTACTGTCAGAATAATTATTTTTCCTCTCACGTTCGGTGCTGGGACCAAGCTGGAAATCAAA Clone 25F5: SEQ ID NOs: 141-150 heavy chain <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- QVQLKQSGAELVKPGASLKLSCKAS GYTFTTYGIN WVRQRPEQGLEWIG WIFPGDATTMYNEKFK GTATLTADKSSS ------FR3------------> CDR3 <---FR4---> TAYMQLSGLTSEDSAVYFCAR FYYGNSFVD WGQGTLVTVSA Nucleic acid sequence CAGGTCCAGCTGAAGCAGTCTGGAGCTGAACTGGTCAAGCCTGGGGCTTCACTCAAGTTGTCCTGCAAGGCTTCTGGCTACACCTTCACAACTTATGGTATAAACTGGGTGAGGCAGAGGCCTGAAACAGGGACTTGAGTGGATTGGATGGATTTTTCCTGGAGATGCCAACCACTATG TACAATGAGAAATTCAAGGGCACGGCCACACTGACTGCAGACAAATCCTCCAGTACAGCCTACATGCAGCTCAGCGGTTGACATCTGAGGACTCTGCTGTCTATTTCTGTGCAAGGTTCTACTACGGTAACTCCTTTGTTGACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Light weight <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPSSLTVTAGEKVTMSC KSSQSLLNSGNQKNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFTGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSVQAEDLAVYYC QNAYYYPLT FGAGTKLEIK nucleic acid sequence GACATTGTGATGACACAGTTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACCTGGTACCAGCAGAAGCCAGGGCAGCCTCCTAAACTGTTGATCTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGCTTATTATTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAAATCAAA
[0142] The heavy and light chain variable region sequence fragments were amplified by PCR, and the heavy chain variable region was cloned into a carrier containing the human heavy chain constant region to express a complete IgG1 heavy chain in mammalian cells. Similarly, the light chain variable region was cloned into a carrier containing the human light chain constant region to express a complete kappa light chain in mammalian cells. After the sequence was correctly determined, HEK293-6E mammalian cells were transfected to express and secrete the IgG1 into the culture medium. The combined supernatant was collected and purified by filtration. IgG was purified using Protein A chromatography. The culture supernatant was loaded onto an appropriately sized Protein A column, washed with 50 mM Tris-HCl (pH 8.0) and 250 mM NaCl, and the bound IgG was eluted with 0.1 M Glycine-HCl (pH 3.0). The protein was concentrated by ultrafiltration using a concentration tube (Millipore), and the IgG concentration was measured by OD280 detection and spectrophotometry. The purity of the IgG was analyzed using SDS-PAGE.
[0143] After digestion of logarithmically growing HEK293-claudin18.1 cells, HEK293-claudin18.2 cells, and HEK293 cells, 5 × 10 4Cells were added to a 96-well U-bottom plate at 100 μL per well and centrifuged at 1100 rpm for 3 minutes. The supernatant was discarded, and the cells were gently shaken to disperse. Serially diluted antibodies (antibody concentrations were 5-fold diluted in eight steps starting from 100 nM) were added at 50 μL per well and incubated at 4°C for 1 hour. After incubation, the wells were washed three times with 140 μL of 0.5% BSA. The second antibody, AlexaFluro647 anti-human IgG (Jackson ImmunoResearch, product number 109-606-170), was added at 30 μL per well and incubated at 4°C for 40 minutes. After incubation, the wells were washed three times with 140 μL of 0.5% BSA. Finally, the wells were resuspended in 50 μL of PBS and analyzed using a flow cytometer (iQue Screener). The results are shown in Figure 4 and Table 1. In Figure 4, flow cytometry (FACS) showed that the resulting chimeric claudin-18.2 IgG1 antibody recognized only claudin-18.2-transfected HEK293-claudin-18.2 cells (Figure 4B), but did not bind to either HEK293 (Figure 4A) or HEK293-claudin-18.1 (Figure 4C).
[0144] [Table 1] [Example]
[0145] <Intracellular antibody uptake experiment> Cells in the logarithmic growth phase were washed once with prewarmed medium and centrifuged at 1000 rpm for 3 minutes. The supernatant was discarded and serum-free medium was added to the cells, and the cells were diluted to 1 × 10 6The cells were resuspended at 200 μL / tube and aspirated into EP tubes. 500 μL of pre-chilled 0.5% BSA / PBS was added and centrifuged at 1000 rpm for 3 minutes. The supernatant was discarded, and 10 μg / mL of antibody was added. The cells were incubated at 37°C for 15, 30, 60, 120, 180, and 240 minutes. After each incubation with the first antibody, the cells were washed twice with 500 μL of pre-chilled 0.5% BSA / PBS. A 1:300 diluted second antibody was then added directly and incubated for 45 minutes. After the second antibody incubation, the cells were washed twice with 500 μL of 0.5% BSA / PBS and resuspended in 200 μL for FACS analysis. The results, as shown in FIG. 5, demonstrated that antibodies such as 15D11, 15F9, 18A9 and 18D10 have the function of mediating cellular uptake. [Example]
[0146] <Humanized anti-claudin 18.2 antibody> The variable region sequences of the selected monoclonal antibodies were compared with human embryonic antibody sequences to find highly homologous sequences and perform CDR grafting. Computer-based homology modeling was then performed to analyze the CDR regions and the surrounding framework amino acid sequences and consider their spatial and steric binding patterns. Electrostatic forces, van der Waals forces, hydrophilicity, and entropy were calculated to identify individual amino acids in the gene sequences of the positive monoclonal antibodies that are important for interacting with the target and maintaining the spatial framework. Based on this, backmutation sites were designed. HLA-DR affinity was analyzed and considered, and a human embryonic framework sequence with low immunogenicity was selected. Amino acid residues that could be modified during the fermentation process were analyzed, and mutations were designed to reduce the likelihood of modification.
[0147] Different heavy and light chain derivatives were designed and synthesized. The light and heavy chain derivatives were then cloned into carriers containing the antibody kappa chain constant region Ckappa or the human IgG1 constant regions CH1-CH3. Similar parental light and heavy chain derivative plasmids were combined and paired, then transfected into HEK293.6E cells and expressed for 5-6 days. The supernatant was collected and purified using a Protein A column. The variable region sequences of the humanized antibodies are as follows:
[0148] 15F9VHv5: SEQ ID NOs: 151-155 <------------FR1---------> CDR1 <------FR2----> CDR2 <---------- QIQLVQSGSELKKPGASVKVSCKAS GYTFTNYGIN WVRQAPGQGLEWMG WINPNTGETTYAEGFT GRFVLSWDTSVS ------FR3------------> CDR3 <---FR4---> TAYLQISSLKAEDTAVYFCAR LYYGNRFDS WGQGTLVTVSS Nucleic acid sequence CAGATTCAGCTGGTGCAGTCTGGCAGCGAGCTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCTAGCGGCTACACATTCACCAACTACGGCATCAACTGGGTCCGACAGGCTCCTGGACAGGGACTCGAATGGATGGGCTGGATCAACCCCAACACCGGCGAGACAACA TACGCCGAGGGCTTCACAGGCAGATTCGTGCTGAGCTGGGATACCAGCGtCAGCACAGCTTACCTGCAGATCaGcAGCCTGAAGGCCGAGGATACCGCCGTGTACTTCTGCGCCAGACTGTACTACGGCAACAGATTCGACTCTTGGGGCCAGGGCACACTGGTCACAGTCTCTTCT 15F9VHv5r1: SEQ ID NOs: 156-160 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLVQSGSELKKPGASVKVSCKAS GYTFTNYGIN WVRQAPGQGLEWMG WINPNTGETTYAEEFK GRFVFSLDTSVS ------FR3-----------> CDR3 <---FR4---> TAYLQISSLKAEDTAVYFCAR LYYGNRFDS WGQGTLVTVSS CAGgtgCAGCTGGTGCAGTCTGGCAGCGAGCTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCTAGCGGCTACACATTCACCAACTACGGCATCAACTGGGTCCGACAGGCTCCTGGACAGGGACTCGAATGGATGGGCTGGATCAACCCCAACACCGGCGAGACAACATACGCCGAGGAGTTCAAGGGCAGATTCGTGtTcAGCctgGATACCAGCgtcAGCACAGCTTACCTGCAGATCaGcAGCCTGAAGGCCGAGGATACCGCCGTGTACTTCTGCGCCAGACTGTACTACGGCAACAGATTCGACTCTTGGGGCCAGGGCACACTGGTCACAGTCTCTTCT 15F9VHv5r2: SEQ ID NO: 161-165 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- EVQLVQSGSELKKPGASVKVSCKAS GYTFTNYGIN WVRQAPGQGLEWMG WINPYTGETTYAEEFK GRFVFSLDTSVS ------FR3-----------> CDR3 <---FR4---> TAYLQISSLKAEDTAVYFCAR LYYGNRFDS WGQGTLVTVSS GAGgtgCAGCTGGTGCAGTCTGGCAGCGAGCTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCTAGCGGCTACACATTCACCAACTACGGCATCAACTGGGTCCGACAGGCTCCTGGACAGGGACTCGAATGGATGGGCTGGATCAACCCCTACACCGGCGAGACAACATACGCCGAGGAGTTCAAGGGCAGATTCGTGtTcAGCctgGATACCAGCgtcAGCACAGCTTACCTGCAGATCaGcAGCctgGAAGGCCGAGGATACCGCCGTGTACTTCTGCGCCAGACTGTACTACGGCAACAGATTCGACTCTTGGGGCCAGGGCACACTGGTCACAGTCTCTTCT 15F9VHv6: SEQ ID NO: 166 - 170 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QIQLVQSGSELKKPGASVKVSCKAS GYTFTNYGIN WVRQAPGQGLEWMG WINPGTGETTYAEGFT GRFVLSWDTSVS ------FR3-----------> CDR3 <---FR4---> TAYLQISSLKAEDTAVYFCAR LYYGNRFDS WGQGTLVTVSS Nucleic acid sequence CAGATTCAGCTGGTGCAGTCTGGCAGCGAGCTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCTAGCGGCTACACATTCACCAACTACGGCATCAACTGGGTCCGACAGGCTCCTGGACAGGGACTCGAATGGATGGGCTGGATCAACCCCGGCACCGGCGAGACAACATACGCCGAGGGCTTCACAGGCAGATTCGTGCTGAGCTGGGATACCAGCGtCAGCACAGCTTACCTGCAGATCaGcAGCCTGAAGGCCGAGGATACCGCCGTGTACTTCTGCGCCAGACTGTACTACGGCAACAGATTCGACTCTTGGGGCCAGGGCACACTGGTCACAGTCTCTTCT 18A9VHv1: SEQ ID NO: 171-175 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLVQSGAEVKKPGSSVKVSCKPS GYAFTNYLID WVRQAPGQGLEWMG GINPGSGDTVYNEKFQ GRVTLTADKSSM ------FR3-----------> CDR3 <---FR4---> TAYMELSSLRSEDTAVYFCAR RVRGNSFDS WGQGTLVTVSS Nucleic acid sequence CAGGTTCAGCTTGGTTCAGTCTGGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGTGTCCTGCAAGCCTTCTGGCTACGCCTTCACCACTACCTGATCGACTGGGTCCGACAGGCTCCTGGACAGGACTTGAATGGATGGGCGGCATCAACCCTGGCAGCGGCGATACAGTG TACAACGAGAAGTTCCAGGGCAGAGTGACCCTGACCGCCGACAAGTCTAGCATGACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATACCGCCGTGTACTTCTGTCCAGAAGAGTGCGGGGCAACAGCTTCGATTCTTGGGGCCAGGGAACCCTGGTCACCGTTTCTTC 18A9VHv2: SEQ ID NO:176-180 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLVQSGAEVKKPGSSVKVSCKPS GYTFTNYLID WVRQAPGQGLEWMG GINPGSGDTVYNEKFQ GRVTLTADESTS ------FR3-----------> CDR3 <---FR4---> TAYMELSSLRSEDTAVYFCAR RVRGNSFDS WGQGTLVTVSS nucleic acid sequence CAGGTTCAGCTTGGTTCAGTCTGGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGTGTCCTGCAAGCCTTCTGGCTACACCTTCACCAACTACCTGATCGACTGGGTCCGACAGGCTCCTGGACAGGGACTTGAATGGATGGGCGGCATCAACCCTGGCAGCGGCGATACAGTG TACAACGAGAAGTTCCAGGGCAGAGTGACCCTGACCGCCGACGAGTCTACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATACCGCCGTGTACTTCTGTCCAGAAGAGTGCGGGGCAACAGCTTCGATTCTTGGGGCCAGGGAACCCTGGTCACCGTTTCTTTCT 18A9VHv3: sequence number 181-185 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLVQSGAEVKKPGSSVKVSCKPS GYTFTNYLID WVRQAPGQGLEWMG GINPGSGDTVYNEKFQ GRVTLTADKSSM ------FR3-----------> CDR3 <---FR4---> TAYMELSSLRSEDTAVYCAR RVRGNSFDS WGQGTLVTVSS nucleic acid sequence CAGGTTCAGCTTGGTTCAGTCTGGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGTGTCCTGCAAGCCTTCTGGCTACACCTTCACCAACTACCTGATCGACTGGGTCCGACAGGCTCCTGGACAGGGACTTGAATGGATGGGCGGCATCAACCCTGGCAGCGGCGATACAGTG TACAACGAGAAGTTCCAGGGCAGAGTGACCCTGACCGCCGACAAGTCTAGCATGACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATACCGCCGTGTACTACTGTGCCAGAAGAGTGCGGGGCAACAGCTTCGATTCTTGGGGCCAGGGAACCCTGGTCACCGTTTCTTCT 18A9VHv4: sequence number 186-190 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLVQSGAEVKKPGSSVKVSCKAS GYTFTNYLID WVRQAPGQGLEWMG GINPGSGDTVYNEKFQ GRVTLTADKSSM ------FR3-----------> CDR3 <---FR4---> TAYMELSSLRSEDTAVYFCAR RVRGNSFDS WGQGTLVTVSS nucleic acid sequence CAGGTTCAGCTTGGTTCAGTCTGGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGTGTCCTGCAAGGCTTCTGGCTACACCTTCACCAACTACCTGATCGACTGGGTCCGACAGGCTCCTGGACAGGGACTTGAATGGATGGGCGGCATCAACCCTGGCAGCGGCGATACAGTG TACAACGAGAAGTTCCAGGGCAGAGTGACCCTGACCGCCGACAAGTCTAGCATGACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATACCGCCGTGTACTTCTGTCCAGAAGAGTGCGGGGCAACAGCTTCGATTCTTGGGGCCAGGGAACCCTGGTCACCGTTTCTTC 18A9VHv5: sequence number 191-195 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLVQSGAEVKKPGSSVKVSCKPS GYTFTNYLID WVRQAPGQGLEWMG GINPGSGDTVYNEKFQ GRVTITADESTS ------FR3-----------> CDR3 <---FR4---> TAYMELSSLRSEDTAVYFCAR RVRGNSFDS WGQGTLVTVSS nucleic acid sequence CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGTGTCCTGCAAGCCTTCTGGCTACACCTTCACCAACTACCTGATCGACTGGGTCCGACAGGCTCCTGGACAGGGACTTGAATGGATGGGCGGCATCAACCCTGGCAGCGGCGATACAGTGTACAACGAGAAGTTCCAGGGCAGAGTGACCATCACCGCCGACGAGTCTACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAAGAGTGCGGGGCAACAGCTTCGATTCTTGGGGCCAGGGAACCCTGGTCACCGTTTCTTCT 18A9VHv6: SEQ ID NO: 196 - 200 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLVQSGAEVKKPGASVKVSCKPS GYAFTNYLID WVRQAPGQGLEWMG GINPGSGDTVYNEKFQ GRVTLTADKSSS ------FR3-----------> CDR3 <---FR4---> TAYMELSSLRSEDTAVYFCAR RVRGNSFDS WGQGTLVTVSS Nucleic acid sequence CAGGTTCAGCTGGTTCAGTCTGGCGCCGGAAGTGAAGAAACCTGGCGCCAGCGTGAAGGTGTCCTGCAAGCCTTCTGGCTCACGCCTTCACCAACTACCTGATCGACTGGGTCCGACAGGCTCCTGGACAGGACTTGAATGGATGGGCGGCATCAACCCTGGCAGCGGCGATACAGTG TACAACGAGAAGTTCCAGGGCAGAGTGACCCTGACCGCCGACAAGTCTAGCAGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATACCGCCGTGTACTTCTGTCCAGAAGAGTGCGGGGCAACAGCTTCGATTCTTGGGGCCAGGGAACCCTGGTCACCGTTCTTCT 18A9VHv7: SEQ ID NO:201-205 <----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLVQSGAEVKKPGASVKVSCKPS GYTFTNYLID WVRQAPGQGLEWMG GINPGSGDTVYNEKFQ GRVTLTADTSTS ------FR3-----------> CDR3 <---FR4---> TWYMELSSLRSEDTAVYFCAR RVRGNSFDS WGQGTLVTVSS nucleic acid sequence CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCAGCGTGAAGGTGTCCTGCAAGCCTTCTGGCTACACCTTCACCAACTACCTGATCGACTGGGTCCGACAGGCTCCTGGACAGGGACTTGAATGGATGGGCGGCATCAACCCTGGCAGCGGCGATACAGTGTACAACGAGAAGTTCCAGGGCAGAGTGACCCTGACCGCCGACACCTCTACCAGCACCGTCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAAGAGTGCGGGGCAACAGCTTCGATTCTTGGGGCCAGGGAACCCTGGTCACCGTTTCTTCT 18D10VHv1: SEQ ID NO: 206-210 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLQESGPGLVKPSETLSLTCTVS GYSITSNYAWN WIRQPPGKGLEWIG YINYSGNTNYNPSLKS RVTISRDTSKN ------FR3-----------> CDR3 <---FR4---> QFSLKLSSVTAADTAVYYCAT SYYGNSFIY WGQGTLVTVSS Nucleic acid sequence CAGGTTCAGCTGCAAGAGTCTGGACCTGGCCTGGTCAAGCCTAGCGAGACACTGAGCCTGACCTGTACCGTGTCCGGCTACAGCATCACCAGCAACTACGCCTGGAACTGGATCAGACAGCCTCCTGGCAAAGGCCTCGAGTGGATCGGCTACATCAACTACAGCGGCAACACCAACTACAACCCCAGCCTGAAGTCCAGAGTGACCATCAGCAGAGACACCAGCAAGAACCAGTTCTCCCTGAAGCTGAGCAGCGTGACAGCCGCCGATACAGCCGTGTACTACTGTGCCACAAGCTACTACGGCAACAGCTTCATCTACTGGGGCCAGGGCACACTGGTCACCGTTTCTTCT 18D10 VH v2: SEQ ID NO: 211-215 / <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLQESGPGLVKPSETLSLTCTVS GGSISSNYAWN WIRQPPGKGLEWMG YINYSGNTNYNPSLKS RITISRDTSKN ------FR3-----------> CDR3 <---FR4---> QFSLKLSSVTAADTAVYYCAT SYYGNSFIY WGQGTLVTVSS Nucleic acid sequence CAGGTTCAGCTGCAAGAGTCTGGACCTGGCCTGGTCAAGCCTAGCGAGACACTGAGCCTGACCTGTACCGTGTCCGGCGGCAGCATCAGCAGCAACTACGCCTGGAACTGGATCAGACAGCCTCCTGGCAAAGGCCTCGAGTGGATGGGCTACATCAACTACAGCGGCAACACCAACTACAACCCCAGCCTGAAGTCCAGAATCACCATCAGCAGAGACACCAGCAAGAACCAGTTCTCCCTGAAGCTGAGCAGCGTGACAGCCGCCGATACAGCCGTGTACTACTGTGCCACAAGCTACTACGGCAACAGCTTCATCTACTGGGGCCAGGGCACACTGGTCACCGTTTCTTCT 18D10 VH v3: SEQ ID NO: 216 - 220 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLQESGPGLVKPSETLSLTCTVS GGSISSNYAWN WIRQPPGKGLEWIG YINYSGNTNYNPSLKS RVTISRDTSKN ------FR3-----------> CDR3 <---FR4---> QFSLKLSSVTAADTAVYYCAT SYYGNSFIY WGQGTLVTVSS Nucleic acid sequence CAGGTTCAGCTGCAAGAGTCTGGACCTGGCCTGGTCAAGCCTAGCGAGACACTGAGCCTGACCTGTACCGTGTCCGGCGGCAGCATCAGCAGCAACTACGCCTGGAACTGGATCAGACAGCCTCCTGGCAAAGGCCTCGAGTGGATCGGCTACATCAACTACAGCGGCAACACCAACTACAACCCCAGCCTGAAGTCCAGAGTGACCATCAGCAGAGACACCAGCAAGAACCAGTTCTCCCTGAAGCTGAGCAGCGTGACAGCCGCCGATACAGCCGTGTACTACTGTGCCACAAGCTACTACGGCAACAGCTTCATCTACTGGGGCCAGGGCACACTGGTCACCGTTTCTTCT 18D10 VH v4: SEQ ID NO: 221 - 225 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLQESGPGLVKPSETLSLTCTVS GGSISSNYAWN WIRQPPGKGLEWIG YINYSGYTNYNPSLKS RVTISRDTSKN ------FR3-----------> CDR3 <---FR4---> QFSLKLSSVTAADTAVYYCAT SYYGNSFIY WGQGTLVTVSS Nucleic acid sequence CAGGTTCAGCTGCAAGAGTCTGGACCTGGCCTGGTCAAGCCTAGCGAGACACTGAGCCTGACCTGTACCGTGTCCGGCGGCAGCATCAGCAGCAACTACGCCTGGAACTGGATCAGACAGCCTCCTGGCAAAGGCCTCGAGTGGATCGGCTACATCAACTACAGCGGCTACACCAACTACAACCCCAGCCTGAAGTCCAGAGTGACCATCAGCAGAGACACCAGCAAGAACCAGTTCTCCCTGAAGCTGAGCAGCGTGACAGCCGCCGATACAGCCGTGTACTACTGTGCCACAAGCTACTACGGCAACAGCTTCATCTACTGGGGCCAGGGCACACTGGTCACCGTTTCTTCT 18D10VHv5: SEQ ID Nos. 226 - 230 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLQESGPGLVKPSETLSLTCTVS GGSISSNYAWN WIRQPPGKGLEWIG YINYSGNTAYNPSLKS RVTISRDTSKN ------FR3-----------> CDR3 <---FR4---> QFSLKLSSVTAADTAVYYCAT SYYGNSFIY WGQGTLVTVSS Nucleic acid sequence CAGGTTCAGCTGCAAGAGTCTGGACCTGGCCTGGTCAAGCCTAGCGAGACACTGAGCCTGACCTGTACCGTGTCCGGCGGCAGCATCAGCAGCAACTACGCCTGGAACTGGATCAGACAGCCTCCTGGCAAAGGCCTCGAGTGGATCGGCTACATCAACTACAGCGGCAACACCGCCTACAACCCCAGCCTGAAGTCCAGAGTGACCATCAGCAGAGACACCAGCAAGAACCAGTTCTCCCTGAAGCTGAGCAGCGTGACAGCCGCCGATACAGCCGTGTACTACTGTGCCACAAGCTACTACGGCAACAGCTTCATCTACTGGGGCCAGGGCACACTGGTCACCGTTTCTTCT 18D10VHv6: SEQ ID Nos. 231 - 235 <-----------FR1---------> CDR1 <-----FR2----> CDR2 <---------- QVQLQESGPGLVKPSETLSLTCTVS GGSISSNYAWN WIRQPPGKGLEWIG YIYYSGNTNYNPSLKS RVTISRDTSKN ------FR3-----------> CDR3 <---FR4---> QFSLKLSSVTAADTAVYYCAT SYYGNSFIY WGQGTLVTVSS Nucleic acid sequence CAGGTTCAGCTGCAAGAGTCTGGACCTGGCCTGGTCAAGCCTAGCGAGACACTGAGCCTGACCTGTACCGTGTCCGGCGGCAGCATCAGCAGCAACTACGCCTGGAACTGGATCAGACAGCCTCCTGGCAAAGGCCTCGAGTGGATCGGCTACATCTACTACAGCGGCAACACCAACTACAACCCCAGCCTGAAGTCCAGAGTGACCATCAGCAGAGACACCAGCAAGAACCAGTTCTCCCTGAAGCTGAGCAGCGTGACAGCCGCCGATACAGCCGTGTACTACTGTGCCACAAGCTACTACGGCAACAGCTTCATCTACTGGGGCCAGGGCACACTGGTCACCGTTTCTTCT 15F9VLv1: SEQ ID NO: 236-240 <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPDSLAVSLGERATINC KSSQSLLNSGNQRNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSLQAEDVAVYYC QNAYYYPLT FGGGTKVEIK Nucleic acid sequence GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACCATCAACTGCAAGAGCAGCCAGAGCCTGCTGAACAGCGGCAACCAGAGAAACTACCTGACCTGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGAGAATCTGGCGTGCCCGATAGATTCAGCGGCAGCGGCTCTGGAACCGACTTCACCCTGACAATCAGCTCCCTGCAGGCCGAGGATGTGGCCGTGTACTACTGTCAGAACGCCTACTACTACCCTCTGACCTTCGGCGGAGGCACCAAGGTGGAAATCAAG 15F9VLv2: SEQ ID Nos. 241 - 245 <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPDSLAVSLGERATINC KSSQSLLNSGNQRNYLA WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSLQAEDVAVYYC QQAYYYPLT FGGGTKVEIK Nucleic acid sequence GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACCATCAACTGCAAGAGCAGCCAGAGCCTGCTGAACAGCGGCAACCAGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGAGAATCTGGCGTGCCCGATAGATTCAGCGGCAGCGGCTCTGGAACCGACTTCACCCTGACAATCAGCTCCCTGCAGGCCGAGGATGTGGCCGTGTACTACTGTCAGCAGGCCTACTACTACCCTCTGACCTTCGGCGGAGGCACCAAGGTGGAAATCAAG 15F9VLv3: SEQ ID Nos. 246 - 250 <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPDSLAVSLGERATINC KSSQSLLYSGNQRNYLA WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSLQAEDVAVYYC QQAYYYPLT FGGGTKVEIK Nucleic acid sequence GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACCATCAACTGCAAGAGCAGCCAGAGCCTGCTGTACAGCGGCAACCAGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGAGAATCTGGCGTGCCCGATAGATTCAGCGGCAGCGGCTCTGGAACCGACTTCACCCTGACAATCAGCTCCCTGCAGGCCGAGGATGTGGCCGTGTACTACTGTCAGCAGGCCTACTACTACCCTCTGACCTTCGGCGGAGGCACCAAGGTGGAAATCAAG 18A9VLv1: SEQ ID NO: 251-255 <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPDSLAVSLGERATINC KSSQSLLNSGNQKNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGKDF FR3-------------> CDR3 <--FR4---> TLTISSLQAEDVAVYYC QNNYFYPLT FGGGTKVEIK Nucleic acid sequence GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACCATCAACTGCAAGAGCAGCCAGAGCCTGCTGAACAGCGGCAACCAGAAGAACTACCTGACCTGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGAGAAAGCGGCGTGCCAGATAGATTCAGCGGCAGCGGCTCTGGAAAGGACTTCACCCTGACAATCAGCTCCCTGCAGGCCGAGGATGTGGCCGTGTACTACTGCCAGAACAACTACTTCTACCCTCTGACCTTCGGCGGAGGCACCAAGGTGGAAATCAAG 18A9VLv2: Sequence numbers 256 - 260 <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPDSLAVSLGERATINC KSSQSLLNSGNQKNYLA WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSLQAEDVAVYYC QQNYFYPLT FGGGTKVEIK Nucleic acid sequence GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACCATCAACTGCAAGAGCAGCCAGAGCCTGCTGAACAGCGGCAACCAGAAGAACTACCTGGCCTGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGAGAAAGCGGCGTGCCAGATAGATTCAGCGGCAGCGGCTCTGGAACCGACTTCACCCTGACAATCAGCTCCCTGCAGGCCGAGGATGTGGCCGTGTACTACTGCCAGCAGAACTACTTCTACCCTCTGACCTTCGGCGGAGGCACCAAGGTGGAAATCAAG 18D10VLv1: Sequence numbers 261 - 265 <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPDSLAVSLGERATINC KSSQSLLNSGNQKNYLT WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSLQAEDVAVYYC QNAYSFPWT FGQGTKVEIK Nucleic acid sequence GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACCATCAACTGCAAGAGCAGCCAGAGCCTGCTGAACAGCGGCAACCAGAAGAACTACCTGACCTGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGAGAAAGCGGCGTGCCAGATAGATTCAGCGGCAGCGGCTCTGGAACCGACTTCACCCTGACAATCAGCTCCCTGCAGGCCGAGGATGTGGCCGTGTACTACTGTCAGAACGCCTACAGCTTCCCCTGGACATTCGGCCAGGGCACCAAGGTGGAAATCAAG 18D10VLv2: SEQ ID NO: 266 - 270 <----------FR1--------> CDR1 <-----FR2-----> CDR2 <------------- DIVMTQSPDSLAVSLGERATINC KSSQSLLNSGNQKNYLA WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGTDF FR3-------------> CDR3 <--FR4---> TLTISSLQAEDVAVYYC QQAYSFPWT FGQGTKVEIK Nucleic acid sequence GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACCATCAACTGCAAGAGCAGCCAGAGCCTGCTGAACAGCGGCAACCAGAAGAACTACCTGGCCTGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGAGAAAGCGGCGTGCCAGATAGATTCAGCGGCAGCGGCTCTGGAACCGACTTCACCCTGACAATCAGCTCCCTGCAGGCCGAGGATGTGGCCGTGTACTACTGTCAGCAGGCCTACAGCTTCCCCTGGACATTCGGCCAGGGCACCAAGGTGGAAATCAAG
Example
[0149] <Biological activity detection of anti-claudin 18.2 humanized antibody> 1) Affinity measurement of humanized antibodies (EC50) Logarithmic growth phase cells were sealed with 3% BSA for 30 minutes and 5 x 10 4 Cells were seeded into a 96-well U-bottom plate at 100 μL per well and centrifuged at 1100 rpm for 3 minutes. The supernatant was discarded, and the cells were gently shaken to disperse. Serially diluted antibodies (eight 5-fold dilutions starting from 100 nM) were added at 50 μL per well and incubated at 4°C for 1 hour. After incubation, the plate was washed three times with 140 μL of 0.5% BSA per well. AF 647 APC anti-human secondary antibody was added at 30 μL per well and incubated for 40 minutes at 4°C. After incubation, the plate was washed three times with 140 μL of 0.5% BSA per well. Finally, the plate was resuspended in 50 μL of PBS per well and subjected to iQue (Intellicyt, USA) detection (see Table 2).
[0150] [Table 2]
[0151] 2) ADCC killing activity of tumor cells by anti-claudin 18.2 humanized antibody. 30 mL of freshly drawn blood was collected and added to a 50 mL centrifuge tube, mixed uniformly with 15 mL of 1x PBS, and then 20 mL of Ficoll.Paque Plus was added to another 50 mL centrifuge tube. 30 mL of the diluted fresh blood was gently added and spread over the surface of the Ficoll.Paque Plus. The tube was then placed at 20°C and centrifuged at 2000 rpm for 30 minutes. After centrifugation, the top layer of serum in the tube was aspirated using a disposable suction tube. The second layer (i.e., tunica albuginea layer) of the four liquid layers (top to bottom) (PBMCs) was aspirated at 10 mL per tube and placed in a 50 mL centrifuge tube. The isolated PBMCs were added to more than three times their volume of 1x PBS, mixed uniformly, and centrifuged at 1300 rpm for 10 minutes at 4°C. The supernatant was removed by aspirating, resuspended in 10 mL of 1x PBS, and counted.
[0152] The PBMCs were cultured in a 5% CO2 incubator at 37°C for 2 hours, centrifuged at 1300 rpm for 10 minutes, the supernatant was removed, and the cells were suspended in pre-warmed 2.5% FBS / RPMI 1640 medium at a density of 8 × 10 6 Adjust to 50 μL / well, i.e., 4 x 10 cells / mL. 5 10 cells / well were plated in a 96-well U-bottom plate, and then 25 μL / well of diluted antibody (6 two-fold dilutions starting from 40 μg / mL) was added. After incubation for 30 minutes in a 37°C, 5% CO2 incubator, 8 × 10 diluted Kato III cells were added. 3 25 μL of cells / well were added and incubated in a 37°C, 5% CO2 incubator for 4 hours. 30 minutes before detection, 2 μL of elution solution (10x) was added to the largest target cells in the well and incubation was continued. After 4 hours, the wells were centrifuged at 1000 rpm for 3 minutes, and 50 μL of the supernatant was placed in a black microtiter plate. LDH was added and 50 μL of substrate was added per well for detection. After 10 minutes, 25 μL of stop solution was added per well to stop the reaction, and the plate was read using a microplate reader (Biotek).
[0153] The results are calculated as follows:
[0154]
number
[0155] The results, as shown in FIG. 6, demonstrated that the humanized recombinant antibodies 18D10, 18A9, and 15F9 all maintained strong ADCC activity.
[0156] 3) CDC cell killing activity of tumor cells by anti-claudin 18.2 humanized antibody. Kato III cells in the logarithmic growth phase were washed with PBS and then cultured at a density of 1 x 10 7The cells were resuspended at 2 × 10 cells / mL and a fixed amount of CFSE (Sigma, 87444-5MG-F) was added to a final concentration of 1 μM. The cells were incubated at room temperature for 10 min, terminated by adding 3 volumes of medium, centrifuged at 1000 rpm for 5 min at 4 °C, and medium was added to bring the cell density to 2 × 10 cells / mL. 6 The cells were then plated onto a 96-well plate at 50 μL / well, and each diluted antibody (antibody was diluted 3-fold in five steps from 30 μg / mL to 0.12 μg / mL) was added at 50 μL / well. Finally, complement diluted to 30% with medium was added at 50 μL / well. After incubation in a 5% CO2 incubator for 2 hours, the cells were removed and centrifuged at 1000 rpm for 3 minutes. The supernatant was discarded, and the cells were mixed with 1:200 diluted PI and 5×10 4 Sulfate latex (Invitrogen, S37227) was mixed uniformly at 100 μL / well and added to a 96-well plate at 100 μL / well. The mixture was incubated on ice for 10 minutes and then subjected to FACS detection. The results are shown in Figure 7. Both the humanized recombinant antibodies 18D10 and 15F9 exhibited strong CDC activity.
[0157] 4) Cellular uptake of humanized antibodies A 10 μg / mL polylysine solution was prepared in PBS, and 0.5 mL was added per well to a 24-well plate. The plate was then incubated at 37°C for 15 to 30 minutes. 4Cells were seeded at 1000 cells / well, and a 10 μg / mL antibody solution was prepared in preheated DMEM medium. The supernatant in the well plate was aspirated, and 0.5 mL of medium containing the corresponding antibody was added per well. The plate was then incubated at 37°C for 30 minutes. The supernatant was carefully aspirated, and 0.5 mL of PBS was added. The plate was then left to stand for 5 minutes. This procedure was repeated three times for washing. 10% formaldehyde was added to each well for 20–40 minutes for fixation. The formaldehyde was carefully aspirated and removed, and 0.5 mL of 0.2% Triton-PBS was added. The plate was then left to stand for 5 minutes. The plate was then washed three times by repeating the above procedure. AF594-F(ab')2 goat anti-hIgG(H+L) secondary antibody solution (1:300) was prepared in PBS, and 100 μL was added per well. The plate was then incubated at room temperature for 45 minutes. The second antibody solution was carefully aspirated and removed, and 0.5 mL of 0.2% Triton-PBS was added. The plate was incubated for 5 minutes. The above procedure was repeated three times for washing. 8 μg / mL human Lamp-1 / CD107a MAb was prepared, and 100 μL was added per well. The plate was incubated for 45 minutes at room temperature. The antibody solution was carefully aspirated and removed, and 0.5 mL of 0.2% Triton-PBS was added. The plate was incubated for 5 minutes. The above procedure was repeated three times for washing. AF488-F(ab')2 goat anti-mIgG(H+L) solution (1:300) was prepared in PBS, and 100 μL was added per well. The plate was incubated for 45 minutes at room temperature. The supernatant was carefully aspirated and removed, and 0.5 mL of 0.1% Triton-PBS was added. The plate was incubated for 5 minutes. The above procedure was repeated three times for washing. A 1μg / mL DAPI solution was prepared in PBS and stained for 5 minutes at room temperature. The supernatant was carefully aspirated and removed. 0.5mL of 0.1% Triton-PBS was added and the cells were left to stand for 5 minutes. The above procedure was repeated three times for washing. The cells were sealed with 90% glycerin and photographed. The results, shown in Figure 8, indicate that the humanized Claudin18.2 antibody primarily binds to the cell membrane, with some of the antibody being internalized into the cells and entering the lysosomes (as indicated by the arrows).
Claims
1. Amino acid sequences of SEQ ID NOs: 2-4, 12-14, 22-24, 32-34, 42-44, 52-54, 62-64, 72-74, 82-84, 92-94, 102-104, 112-114, 122-124, 132-134, 142-144, 152-154, 157-159, 162-164, 167-169, 172-174, 177-179, 182-184, 187-189, 192-194, 197-199, 202-204, 207-209, 212-214, 217-219, 222-224, 227-229, 232-234 or any of the above. and / or a light chain CDR selected from the amino acid sequences of SEQ ID NOs: 7-9, 17-19, 27-29, 37-39, 47-49, 57-59, 67-69, 77-79, 87-89, 97-99, 107-109, 117-119, 127-129, 137-139, 147-149, 237-239, 242-244, 247-249, 252-254, 257-259, 262-264, 267-269, or any variant thereof.
2. heavy chain CDR1 selected from amino acid sequences SEQ ID NO: 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, 132, 142, 152, 157, 162, 167, 172, 177, 182, 187, 192, 197, 202, 207, 212, 217, 222, 227, 232 or any variant thereof; heavy chain CDR2 selected from amino acid sequence SEQ ID NOs: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, 124, 134, 144, 154, 159, 164, 169, 174, 179, 184, 189, 194, 199, 204, 209, 214, 219, 224, 229, 234 or any variant thereof; and / or a light chain CDR1 selected from the amino acid sequences SEQ ID NOs: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 237, 242, 247, 252, 257, 262, 267 or any variant thereof; 2. The antibody or antigen-binding portion thereof of claim 1, comprising a light chain CDR2 selected from SEQ ID NO: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, 129, 139, 149, 239, 244, 249, 254, 259, 264, 269, or any variant thereof, and a light chain CDR3 selected from SEQ ID NO: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, 129, 139, 149, 239, 244, 249, 254, 259, 264, 269, or any variant thereof.
3. 3. The antibody or antigen-binding portion thereof according to claim 1 or 2, comprising a heavy chain variable region selected from the amino acid sequences of SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 156, 161, 166, 171, 176, 181, 186, 191, 196, 201, 206, 211, 216, 221, 226, 231, or any variant thereof, and / or a light chain variable region selected from the amino acid sequences of SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 236, 241, 246, 251, 256, 261, 266, or any variant thereof.
4. (1) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 152-154, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 237-239; (2) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 152-154, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 242-244; (3) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 152-154, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 247-249. (4) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 157-159, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 237-239; (5) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 157-159, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 242-244; (6) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 157-159, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 247-249. R3 sequences, (7) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 162-164, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 237-239, (8) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 162-164, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 242-244, (9) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 162-164, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 247-249. and CDR3 sequences, (10) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 167-169, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 237-239, (11) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 167-169, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 242-244, (12) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 167-169, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 247-249,(13) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 172-174, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 252-254, respectively; (14) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 172-174, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 257-259, respectively; (15) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 177-179, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 252-254, respectively. (16) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 177-179, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 257-259; (17) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 182-184, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 252-254; (18) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 182-184, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 25 (19) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 187-189, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 252-254, respectively; (20) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 187-189, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 257-259, respectively; (21) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 192-194, respectively, and / or (22) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 192-194, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 257-259; (23) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 197-199, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 252-254; (24) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 197-199;and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 257-259, (25) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 202-204, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 252-254, (26) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 202-204, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 257-259, (27) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 207-209 (28) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 207-209, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 267-269; (29) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 212-214, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 262-264; (30) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 212-214. (31) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 217-219, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 262-264; (32) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 217-219, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 267-269; (33) sequences each comprising (34) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 222-224, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 267-269, respectively; (35) heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 227-229, respectively, and / or light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 262-264, respectively;(36) The antibody or antigen-binding portion thereof according to any one of the preceding claims, comprising the following heavy and light chain CDR combinations: heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 227-229, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 267-269; (37) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 232-234, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 262-264; (38) heavy chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 232-234, and / or light chain CDR1, CDR2 and CDR3 sequences each comprising SEQ ID NO: 267-269.
5. The antibody or antigen-binding portion thereof of any one of the preceding claims, wherein the antibody or antigen-binding portion thereof is humanized.
6. A nucleic acid molecule encoding an antibody or antigen-binding portion thereof according to any one of the preceding claims, or a nucleic acid molecule having at least 60% or more, and more than 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity thereto.
7. A carrier comprising the nucleic acid according to claim 6.
8. A cell or a kit comprising the carrier according to claim 7.
9. A pharmaceutical composition comprising the antibody or antigen-binding portion thereof according to any one of claims 1 to 5, or the nucleic acid according to claim 6, the carrier according to claim 7, or the cell or kit according to claim 8.
10. Use of the antibody or antigen-binding portion thereof according to any one of claims 1 to 5, or the nucleic acid according to claim 6, or the carrier according to claim 7, or the cell or kit according to claim 8, or the pharmaceutical composition according to claim 9, in the preparation of a drug or kit for treating cancer in a mammal, optionally wherein the cancer is gastric cancer, and optionally wherein the antibody kills cancer cells by ADCC or CDC action, and optionally wherein the antibody is conjugated to another cytotoxic drug.
Citation Information
Patent Citations
Antibodies against claudin 18.2, which are useful for cancer diagnosis.
JP2015517476A
Agents for treating cancerous diseases that express claudin
JP2016500059A
